https://trial.medpath.com/news/9af9fc6d1e232a6f/daewoong-pharmaceutical-launches-nabota-botulinum-toxin-in-qatar-completing-gulf-market-expansion 2025-06-13T14:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/26dd80afdb50c2a5/medera-showcases-human-mini-heart-technology-breakthroughs-at-isscr-2025-advancing-gene-therapy-clinical-trials 2025-06-13T13:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/ccdb0cea472e6e1d/who-s-mrna-technology-transfer-programme-enters-phase-2-0-targeting-commercial-scale-production-in-low-and-middle-income-countries 2025-06-13T13:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/7aa8ff1de0acae09/mrd-testing-emerges-as-key-decision-tool-for-post-transplant-multiple-myeloma-management 2025-06-13T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/4dbf5a64b2890fd3/bcma-targeted-bispecific-antibody-cm336-shows-promise-for-refractory-autoimmune-hemolytic-anemia-in-nejm-study 2025-06-13T12:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/d0f3f239033ecf8b/dry-eye-disease-affects-16-4-million-americans-as-new-targeted-therapies-enter-development-pipeline 2025-06-13T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/ce6470fe557c0c77/radiomedix-launches-raha-100-bench-top-generator-to-expand-lead-212-supply-for-targeted-alpha-therapy 2025-06-13T10:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/f664f8c6f085cd19/novel-therapies-show-promise-for-idiopathic-pulmonary-fibrosis-and-progressive-pulmonary-fibrosis-treatment 2025-06-13T10:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/d4e3e71db20b6075/fda-approves-first-in-human-trial-for-novel-car-t-therapy-targeting-neuroblastoma 2025-06-13T08:49:33+00:00 hourly 0.9 https://trial.medpath.com/news/26011dee6fbb03d4/large-real-world-study-finds-no-increased-cancer-or-cardiovascular-risk-with-jak-inhibitors-in-rheumatoid-arthritis 2025-06-13T08:49:31+00:00 hourly 0.9 https://trial.medpath.com/news/0be1a2a7daabaa99/mitsubishi-research-institute-and-astellas-partner-to-accelerate-japanese-drug-discovery-startups 2025-06-13T08:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/873d4c2c400fe7a6/merry-life-advances-first-in-class-alzheimer-s-drug-tml-6-to-global-phase-ii-trial 2025-06-13T08:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/60adb5e3c68bc995/quince-therapeutics-secures-up-to-22-million-to-advance-phase-3-ataxia-telangiectasia-trial 2025-06-13T08:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/a127a8153a191858/viz-ai-receives-first-fda-clearance-for-ai-powered-subdural-hemorrhage-measurement-technology 2025-06-13T05:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/22d3ea472ce392a6/prolaris-genomic-test-advances-personalized-prostate-cancer-treatment-with-precision-therapy-selection 2025-06-13T05:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/3db98fdfe1457229/innovent-to-present-phase-3-results-of-dual-glp-1-glucagon-receptor-agonist-mazdutide-at-ada-2025 2025-06-13T03:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/186bb134344c6e02/early-colorectal-cancer-screening-at-age-40-reduces-death-risk-by-39-taiwan-study-shows 2025-06-13T03:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/2142ee7152ee2943/gensight-biologics-secures-french-regulatory-pathway-for-lumevoq-gene-therapy-in-rare-blindness-disease 2025-06-13T02:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/d3cf3f630b2985ca/nhs-becomes-first-health-system-globally-to-approve-trojan-horse-cancer-therapy-for-multiple-myeloma 2025-06-13T01:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/e6b8368432d5c850/iom-bioworks-secures-rs-4-crore-seed-funding-to-advance-ai-powered-gut-microbiome-healthcare-platform 2025-06-13T01:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/926590190d0f77b8/starton-therapeutics-launches-phase-2a-trial-for-continuous-low-dose-lenalidomide-in-multiple-myeloma 2025-06-13T01:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/0da352889dd013fe/australian-researchers-launch-world-first-clinical-trial-of-pmr-116-to-target-undruggable-myc-driven-cancers 2025-06-13T01:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/ee3071e2705d43b1/elanco-s-zenrelia-receives-positive-eu-regulatory-opinion-for-canine-allergic-dermatitis-treatment 2025-06-13T01:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/adc9a5a9938c546a/merck-animal-health-receives-eu-regulatory-milestone-for-first-in-class-jak-inhibitor-numelvi-for-canine-allergic-dermatitis 2025-06-13T01:02:02+00:00 hourly 0.9 https://trial.medpath.com/news/4084c8d48d2fc5ac/cancer-pain-market-poised-for-transformation-with-novel-non-opioid-therapies-by-2034 2025-06-13T01:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/38306330e50166c5/tazemetostat-pinometostat-combination-shows-promise-for-b-cell-lymphoma-treatment-resistance 2025-06-13T00:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/5205f4e600686641/silence-therapeutics-reports-promising-phase-1-data-for-divesiran-in-polycythemia-vera-at-eha-2025 2025-06-13T00:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/ebad7bdea00ca36f/fda-approves-roche-abbvie-s-venclexta-plus-gazyva-as-first-line-chemotherapy-free-treatment-for-cll 2025-06-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3f20e7affeba891b/tekton-research-adds-fourth-clinical-site-in-2025-with-richmond-pediatric-associates-partnership 2025-06-12T23:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/a1306cbc0d6eeaa0/ouro-medicines-initiates-phase-1b-trial-of-om336-in-autoimmune-cytopenias-following-fda-orphan-drug-designation 2025-06-12T23:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/fcc7e564e9485061/courage-therapeutics-appoints-giovanni-ferrara-as-ceo-to-advance-melanocortin-targeted-obesity-treatments 2025-06-12T21:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/4ad33c02f87839e4/fda-approves-first-non-surgical-treatment-for-non-muscle-invasive-bladder-cancer 2025-06-12T21:11:28+00:00 hourly 0.9 https://trial.medpath.com/news/98e77df6f05f4827/major-us-pharmaceutical-wholesalers-expand-market-control-through-strategic-practice-management-acquisitions 2025-06-12T21:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/de5b4b440970e1bb/bbot-s-bbo-10203-shows-broad-anti-tumor-activity-in-science-publication-advances-to-phase-1-trial 2025-06-12T21:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/74e759cf71ed62d2/autonomize-ai-secures-28-million-series-a-to-scale-ai-driven-healthcare-operations-platform 2025-06-12T21:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/4390129b1f23c989/european-commission-grants-orphan-drug-designation-to-florbetaben-18f-for-attr-amyloidosis-diagnosis 2025-06-12T21:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/78ba895f2e5a6b69/parallel-bio-raises-21-million-series-a-to-revolutionize-drug-discovery-with-human-organoid-platform 2025-06-12T21:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/8f7c9cc1ff319248/specialised-therapeutics-expands-incyte-partnership-to-bring-two-novel-cancer-therapies-to-asia-pacific 2025-06-12T20:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/c44001801bb7d144/apex-labs-expands-phase-2b-psilocybin-ptsd-trial-to-israel-with-ministry-of-health-approval 2025-06-12T20:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/f36d5ac06ae872cb/johnson-johnson-s-bleximenib-shows-promising-results-in-phase-1b-aml-trial-with-82-response-rate 2025-06-12T18:01:36+00:00 hourly 0.9 https://trial.medpath.com/news/899ab4bc1377a076/federal-circuit-upholds-invalidation-of-agilent-s-crispr-guide-rna-patents-in-synthego-victory 2025-06-12T18:00:38+00:00 hourly 0.9 https://trial.medpath.com/news/3702c211f0113fb0/scinai-immunotherapeutics-secures-1-38m-funding-as-cdmo-business-accelerates-toward-2m-revenue-target 2025-06-12T17:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/b93d340f77afa271/biofrontera-inc-negotiates-strategic-partnership-changes-with-german-parent-company 2025-06-12T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/a7b4e927069fd5fb/alys-pharmaceuticals-advances-first-in-class-mast-cell-selective-c-kit-inhibitor-aly-301-to-clinical-trials-for-cold-urticaria 2025-06-12T17:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/5efc8a30577d0005/hoth-therapeutics-secures-japanese-patent-for-novel-mast-cell-targeting-platform-ht-kit 2025-06-12T17:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/91e553ca77eb3b87/volition-s-nu-q-h3-1-biomarker-shows-promise-for-sepsis-assessment-in-large-icu-study 2025-06-12T17:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/cc3b299bb2d7cbf3/cmv-treatment-pipeline-expands-with-20-therapies-from-leading-pharmaceutical-companies 2025-06-12T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/8cb5a319b313500d/chlorhexidine-impregnated-central-venous-catheters-reduce-icu-bloodstream-infections-by-70-5-in-multinational-study 2025-06-12T17:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/97539135aee9d598/vascarta-s-vasceptor-receives-fda-orphan-drug-designation-for-sickle-cell-disease-treatment 2025-06-12T17:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/c2b154008659d2e4/adc-therapeutics-secures-100-million-financing-to-advance-zynlonta-development-through-2028 2025-06-12T17:13:56+00:00 hourly 0.9 https://trial.medpath.com/news/cab0cd5d1ec2ceb2/dyne-therapeutics-reports-breakthrough-preclinical-results-for-fshd-gene-therapy-dyne-302 2025-06-12T17:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/eea8788a79df5498/rebel-medicine-secures-6m-series-a-funding-and-fda-ind-clearance-for-non-opioid-pain-therapy-alevatrix 2025-06-12T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/3511fa75b4e90356/bullfrog-ai-partners-with-sygnature-discovery-to-expand-ai-driven-drug-discovery-platform-access 2025-06-12T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/f6c6c9216550fbdf/predictive-oncology-develops-exclusive-3d-liver-toxicity-models-for-labcorp-to-accelerate-drug-discovery 2025-06-12T17:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/806afed26246ee7f/alzecure-receives-fda-support-for-acd440-development-in-rare-pain-disorder-erythromelalgia 2025-06-12T17:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/42ab3862652a4106/fda-grants-fast-track-designation-to-sumitomo-s-nuvisertib-for-myelofibrosis-treatment 2025-06-12T17:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/7acf2a742587ecff/syensqo-opens-world-s-largest-microbiology-lab-in-france-to-accelerate-biodegradable-product-development 2025-06-12T17:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/aa09938d8852cad8/aim-immunotech-secures-manufacturing-patent-for-ampligen-through-2041 2025-06-12T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/da0e140847a424bd/screenin3d-secures-ps750000-to-accelerate-cancer-drug-development-with-lab-on-a-chip-technology 2025-06-12T17:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/25a1cc595a294b0b/amneal-secures-fda-approval-for-generic-prednisolone-acetate-eye-drops-targeting-201-million-market 2025-06-12T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/0d53025e5f96fe60/nanoform-initiates-pivotal-bioequivalence-studies-for-nanoenzalutamide-prostate-cancer-treatment 2025-06-12T17:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/cea4d7109801a179/immunoprecise-s-ai-designed-glp-1-peptides-outperform-semaglutide-in-receptor-activation-studies 2025-06-12T14:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/ae59d55229942cce/mina-therapeutics-reports-breakthrough-pre-clinical-results-for-rna-based-sickle-cell-disease-treatment 2025-06-12T14:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/00cfe1646db4dad4/comprehensive-analysis-reveals-943-autoimmune-collaboration-and-licensing-deals-across-30-diseases-from-2016-2025 2025-06-12T12:51:42+00:00 hourly 0.9 https://trial.medpath.com/news/c04d093db3eb4e96/biontech-to-acquire-curevac-for-1-25-billion-to-strengthen-mrna-cancer-immunotherapy-pipeline 2025-06-12T12:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/11da4c5f148370b6/sensible-biotechnologies-achieves-90-reduction-in-mrna-optimization-time-using-ai-powered-platform 2025-06-12T12:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/804ad7c65c001ed9/cytiva-completes-1-6-billion-global-manufacturing-expansion-to-boost-biopharmaceutical-supply-chain 2025-06-12T12:49:50+00:00 hourly 0.9 https://trial.medpath.com/news/6365d4e822583b8b/kaist-researchers-develop-antibody-treatment-to-restore-vision-in-retinitis-pigmentosa 2025-06-12T12:47:56+00:00 hourly 0.9 https://trial.medpath.com/news/e4c4ad6a68dea9c0/merck-launches-phase-3-trial-for-single-dose-dengue-vaccine-v181-targeting-global-public-health-crisis 2025-06-12T12:46:36+00:00 hourly 0.9 https://trial.medpath.com/news/3408fd3e1e1e9e1a/novel-antimicrobial-strategies-show-promise-against-drug-resistant-pathogens 2025-06-12T10:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/91bb7f6768e8a8de/mezzion-secures-20-million-to-advance-phase-3-trial-of-udenafil-for-rare-congenital-heart-disease 2025-06-12T09:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/4e9b01bce8de0bd9/spikimm-secures-worldwide-license-for-anti-bk-virus-monoclonal-antibodies-to-protect-transplant-patients 2025-06-12T09:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/d06f57ad410ecf71/astrivax-therapeutics-appoints-former-bayer-pharma-ceo-dieter-weinand-as-board-chairman 2025-06-12T09:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/ea9c6c3de8b2f115/enterome-secures-19-million-to-advance-novel-oncomimics-immunotherapy-for-indolent-non-hodgkin-lymphoma 2025-06-12T09:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/11eb2c004d33c9bd/crispr-therapeutics-reports-breakthrough-results-from-in-vivo-gene-therapy-ctx310-for-heart-disease 2025-06-12T09:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/55a8b4aaa402a3ca/samsung-bioepis-reports-sustained-safety-profile-for-epysqli-biosimilar-in-long-term-pnh-study 2025-06-12T09:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/c4d70e55373c79c3/snipr-biome-doses-first-patient-with-crispr-armed-phage-therapy-snipr001-for-drug-resistant-e-coli-prevention 2025-06-12T09:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/7f4272a746bfd896/cytovale-s-intellisep-diagnostic-reduces-sepsis-mortality-by-39-in-large-real-world-study 2025-06-12T08:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/fcbca631f7b03c19/mro-acquires-q-centrix-to-create-comprehensive-clinical-data-management-platform 2025-06-12T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/0dc90f59d0faed5d/moleculight-fluorescence-imaging-demonstrates-superior-outcomes-in-deep-sternal-wound-infections-reducing-costs-and-complications 2025-06-12T06:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/acdc07577ccfffc2/cognito-therapeutics-spectris-ad-demonstrates-significant-delay-in-alzheimer-s-disease-progression-through-non-invasive-neuromodulation 2025-06-12T06:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/accc4a915bac81a4/qlaris-bio-develops-novel-fixed-dose-combination-therapy-targeting-unaddressed-component-of-glaucoma-treatment 2025-06-12T06:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/78ba3a118d8f7cd9/juvena-therapeutics-partners-with-eli-lilly-in-ai-driven-muscle-health-drug-discovery-collaboration 2025-06-12T05:03:16+00:00 hourly 0.9 https://trial.medpath.com/news/aa5107816cd68ac5/rutgers-study-challenges-fda-heart-safety-warning-for-epilepsy-drug-lamotrigine 2025-06-12T05:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/9871adabdd744202/rfk-jr-replaces-entire-cdc-vaccine-advisory-committee-with-eight-new-members 2025-06-12T03:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/f249d7b2d43062b1/subcutaneous-oncology-drug-delivery-transforms-cancer-care-with-fda-approved-formulations 2025-06-12T03:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/500abdb42247a9f9/toripalimab-emerges-as-preferred-pd-1-inhibitor-for-metastatic-nasopharyngeal-carcinoma-despite-access-challenges 2025-06-12T03:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/04b4640a3631ec30/monopar-therapeutics-launches-fda-authorized-expanded-access-program-for-upar-targeted-radiopharmaceuticals-in-advanced-cancers 2025-06-12T01:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/04eb4a5c665e37af/molecular-partners-reports-promising-response-rates-with-optimized-mp0533-dosing-in-relapsed-refractory-aml 2025-06-12T01:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/71f92eefd61d3340/skin-biopsy-test-detects-neurodegenerative-biomarker-in-75-of-rem-sleep-disorder-patients 2025-06-12T01:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/3cb6bea76e3bef40/olaparib-temozolomide-combination-fails-to-improve-outcomes-in-advanced-uterine-leiomyosarcoma 2025-06-12T01:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/f2cc87d9e5808e66/moderna-seeks-external-partners-to-fund-late-stage-vaccine-trials-for-latent-virus-programs 2025-06-12T01:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/884411a7637593fe/university-at-buffalo-develops-novel-non-opioid-molecule-for-long-lasting-chronic-pain-relief 2025-06-12T00:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/b8eb4378d62cfced/sandoz-completes-11-2-billion-spin-off-from-novartis-becomes-independent-generics-leader 2025-06-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5efd0f160041e5f8/ryght-ai-secures-3m-seed-funding-and-expands-academic-partnerships-to-accelerate-clinical-trial-site-selection 2025-06-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d0ab95cce6178d3a/fda-accepts-tamarack-biotics-uv-light-milk-treatment-technology-as-safe-alternative-to-traditional-pasteurization 2025-06-11T21:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/8f3cf8413b9373a5/fda-approves-new-tablet-formulation-of-brukinsa-for-all-indications-reducing-pill-burden-for-b-cell-cancer-patients 2025-06-11T21:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/2bce0ba0ac06b307/aspirin-shows-no-benefit-and-potential-harm-in-colorectal-cancer-liver-metastases-phase-3-trial-finds 2025-06-11T21:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/e8e2a9ec5f69831e/t1d-exchange-to-present-13-real-world-data-studies-at-ada-2025-scientific-sessions 2025-06-11T21:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/9027e5ddee0196c5/okyo-pharma-s-eye-pain-drug-trial-ends-early-analysts-raise-price-target-60-on-accelerated-timeline 2025-06-11T21:00:55+00:00 hourly 0.9 https://trial.medpath.com/news/607c1477b0aad444/northwest-biotherapeutics-to-present-next-generation-dendritic-cell-therapy-advances-at-cancer-immunotherapy-conference 2025-06-11T20:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/de7d0a3888d98eb0/nusano-achieves-99-2-purity-in-gadolinium-160-enrichment-opens-190000-square-foot-utah-facility 2025-06-11T20:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/d459b8e30ca865a7/bristol-myers-squibb-acquires-novel-prostate-cancer-radiopharmaceutical-for-1-35-billion 2025-06-11T20:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/e7f615f17c72cbaf/uniqure-appoints-kylie-o-keefe-as-chief-customer-and-strategy-officer-to-lead-amt-130-commercialization-for-huntington-s-disease 2025-06-11T20:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/d35ffa8a5a2e6896/biovica-sets-ambitious-revenue-targets-following-strategic-partnerships-in-cancer-monitoring 2025-06-11T20:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/5dcad14b07a4dde6/sofinnova-partners-and-nvidia-launch-ai-infrastructure-partnership-to-accelerate-european-life-sciences-innovation 2025-06-11T18:00:17+00:00 hourly 0.9 https://trial.medpath.com/news/26c97d31581b1e28/lifordi-presents-promising-preclinical-data-for-lfd-200-glucocorticoid-adc-at-eular-2025 2025-06-11T17:13:55+00:00 hourly 0.9 https://trial.medpath.com/news/de9182474cd0f4ff/setpoint-medical-s-neuroimmune-modulation-platform-receives-eular-clinical-research-award-for-rheumatoid-arthritis-trial 2025-06-11T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/46501e3646dcef2c/fda-approves-mavyret-as-first-treatment-for-acute-hepatitis-c-with-96-cure-rate-in-eight-weeks 2025-06-11T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/b5657bcaf870c32f/zeteo-biomedical-secures-global-patents-for-advanced-drug-delivery-technologies-supporting-space-based-healthcare 2025-06-11T17:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/785a50a704071c53/nanobody-platform-enhances-cancer-immunotherapy-through-albumin-hitchhiking-and-sting-activation 2025-06-11T17:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/b15e26d1347d871e/chiesi-group-and-key2brain-expand-partnership-with-worldwide-licensing-deal-for-blood-brain-barrier-crossing-therapies 2025-06-11T17:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/20174321fbe57f37/cabaletta-bio-launches-public-offering-to-fund-car-t-cell-therapy-development-for-autoimmune-diseases 2025-06-11T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/b62e2e130fc8c898/graves-disease-pipeline-shows-promise-with-10-therapies-in-development-as-ted-treatments-gain-regulatory-momentum 2025-06-11T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/a749c6b0dc4b00fb/essilorluxottica-acquires-european-ophthalmology-network-optegra-to-advance-med-tech-strategy 2025-06-11T17:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/571640ec6aa7ef43/simtra-biopharma-solutions-and-milliporesigma-form-strategic-alliance-to-streamline-adc-manufacturing 2025-06-11T17:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/3b09513c6d361282/elkedonia-raises-eur11-25-million-to-develop-novel-neuroplastogen-therapy-for-treatment-resistant-depression 2025-06-11T17:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/3f20a6508b5cdf08/harmony-biosciences-bp1-15205-shows-breakthrough-potential-as-best-in-class-narcolepsy-treatment 2025-06-11T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/679f9c6bbb848fe9/walnut-hill-medical-selected-as-fda-tap-program-advisor-to-accelerate-medical-device-patient-access 2025-06-11T17:02:08+00:00 hourly 0.9 https://trial.medpath.com/news/4da4ef131bfead4d/seastar-medical-s-scd-therapy-receives-2-million-dod-grant-for-military-burn-and-sepsis-research 2025-06-11T17:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/5b65037f0f0a63e5/medable-launches-ai-powered-partner-program-to-accelerate-clinical-trial-startup-by-50 2025-06-11T16:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/5adf1cd6c919766d/cellectar-s-iopofosine-i-131-doubles-survival-in-pediatric-brain-cancer-trial 2025-06-11T16:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/dde572d522492fd2/energenesis-biomedical-advances-first-in-class-parkinson-s-disease-therapy-energi-f705pd-toward-phase-i-data-readout 2025-06-11T16:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/1b91e1f484949f12/phase-ii-trial-combines-personalized-neoantigen-vaccines-with-radiotherapy-for-advanced-cancer-treatment 2025-06-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cda21f8574f59bb6/induction-chemoimmunotherapy-shows-non-inferior-outcomes-to-consolidation-therapy-in-stage-iii-nsclc 2025-06-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0569dd290fe68cee/ascend-advanced-therapies-achieves-gmp-certification-for-aav-gene-therapy-quality-control-in-munich 2025-06-11T15:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/5338a7f4968c9e05/cogent-biosciences-secures-400m-debt-financing-to-advance-bezuclastinib-through-pivotal-trials 2025-06-11T15:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/287d67d25c1d13a4/triplet-therapy-shows-superior-efficacy-in-braf-mutant-melanoma-brain-metastases 2025-06-11T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2087145d102fcc0f/capstan-therapeutics-initiates-first-in-human-trial-of-novel-in-vivo-car-t-therapy-for-autoimmune-diseases 2025-06-11T14:01:50+00:00 hourly 0.9 https://trial.medpath.com/news/88035f91e69d539a/oncolytics-biotech-appoints-2b-deal-architect-as-ceo-to-advance-pelareorep-immunotherapy 2025-06-11T13:00:05+00:00 hourly 0.9 https://trial.medpath.com/news/6735530ade102978/novo-nordisk-launches-new-phase-3-trial-for-cagrisema-following-mixed-redefine-1-results 2025-06-11T12:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/243f36939975a5d9/cantargia-s-nadunolimab-receives-fda-fast-track-designation-for-metastatic-pancreatic-cancer 2025-06-11T12:57:17+00:00 hourly 0.9 https://trial.medpath.com/news/e67b6defe47b1555/iqvia-and-nvidia-launch-ai-orchestrator-agents-to-accelerate-clinical-research-and-drug-development 2025-06-11T12:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/430865ca7eafbac2/memo-therapeutics-demonstrates-therapeutic-antibodies-can-cross-kidney-barrier-supporting-bk-virus-treatment-approach 2025-06-11T11:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/bbfce53f1a6c7cf8/israeli-researchers-develop-bioengineered-skin-graft-that-accelerates-burn-healing-by-50 2025-06-11T10:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/ba1850c35e59c876/bayer-and-broad-institute-extend-cardiovascular-research-partnership-through-2030 2025-06-11T10:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/054d8e05f3c00801/bristol-myers-squibb-subsidiary-rayzebio-acquires-oncoacp3-radiopharmaceutical-for-prostate-cancer-in-1-35-billion-deal 2025-06-11T10:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/39ec1048440b4c05/splicebio-raises-135-million-series-b-to-advance-first-dual-aav-gene-therapy-for-stargardt-disease 2025-06-11T10:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/956d410c506f3144/china-approves-first-in-class-influenza-drug-onradivir-targeting-novel-pb2-protein 2025-06-11T09:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/674a85743593dd1e/splicebio-raises-135-million-series-b-to-advance-gene-therapy-for-stargardt-disease-using-novel-protein-splicing-platform 2025-06-11T09:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/05e2d9a0ac55c29a/maxcyte-and-ori-biotech-partner-to-enhance-car-t-cell-manufacturing-through-platform-integration 2025-06-11T09:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/e37f73265b387183/bioinvent-s-bi-1206-shows-promising-phase-1-results-in-combination-with-pembrolizumab-for-solid-tumors 2025-06-11T09:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/2533c4656defd53b/solvonis-therapeutics-launches-ai-powered-cns-drug-discovery-platform-for-depression-and-addiction 2025-06-11T09:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/5ff48652f958acf1/daewoong-pharmaceutical-partners-with-salipro-biotech-to-target-challenging-membrane-proteins-for-drug-discovery 2025-06-11T09:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/9ca0fa12c0fa4a1b/genepowerx-partners-with-mgi-tech-to-advance-ai-powered-genomic-solutions-for-personalized-medicine 2025-06-11T09:01:02+00:00 hourly 0.9 https://trial.medpath.com/news/f534fb4237fcabab/cadila-pharmaceuticals-launches-biscado-bisoprolol-to-address-india-s-cardiovascular-disease-burden 2025-06-11T08:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/fe1a9d20417a7a6f/hemab-therapeutics-advances-bleeding-disorder-pipeline-with-promising-clinical-data-at-isth-2025 2025-06-11T08:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/adea9fee51295cb7/xl-protein-grants-worldwide-license-to-grifols-for-pasylation-enhanced-biopharmaceutical-development 2025-06-11T07:02:12+00:00 hourly 0.9 https://trial.medpath.com/news/454b3246664f9571/xprotm-shows-promise-in-reducing-alzheimer-s-pathology-following-traumatic-brain-injury-in-preclinical-study 2025-06-11T06:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/e3b23c040a5de676/femasys-partners-with-carolinas-fertility-institute-to-expand-femaseed-access-across-north-carolina-network 2025-06-11T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f3227cc56e531c55/weekly-oral-risperidone-shows-promise-for-schizophrenia-treatment-in-phase-3-trial 2025-06-11T05:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/85af5286429a3eb9/onesource-specialty-pharma-partners-with-xbrane-biopharma-for-commercial-biosimilar-manufacturing 2025-06-11T05:02:03+00:00 hourly 0.9 https://trial.medpath.com/news/d9045b497da15f94/cyclopharm-secures-maximum-5-year-us-patent-extension-for-technegas-lung-imaging-agent-through-2031 2025-06-11T05:02:02+00:00 hourly 0.9 https://trial.medpath.com/news/099fedaf205e5094/modified-dash-diet-shows-significant-blood-pressure-benefits-in-type-2-diabetes-patients 2025-06-11T05:00:30+00:00 hourly 0.9 https://trial.medpath.com/news/8d0e1cef4f09ba85/angle-s-parsortix-system-enables-breakthrough-cancer-research-revealing-ctc-clusters-as-key-metastatic-drivers 2025-06-11T03:02:53+00:00 hourly 0.9 https://trial.medpath.com/news/59d6000f8609bf23/hypha-labs-advances-ai-powered-mushroom-cultivation-technology-with-new-patent-filings 2025-06-11T02:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/f4aa42edb82f1543/antibiotic-ciprofloxacin-shows-novel-ace-inhibition-mechanism-opening-path-to-improved-hypertension-therapies 2025-06-11T00:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/99eb26502fa10ca6/eli-health-raises-12m-series-a-to-commercialize-instant-saliva-based-hormone-monitoring-system 2025-06-11T00:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/2f6d4364b84b7dd1/network-meta-analysis-reveals-comparable-cardiovascular-benefits-between-pcsk9-inhibitors-alirocumab-and-evolocumab 2025-06-11T00:47:13+00:00 hourly 0.9 https://trial.medpath.com/news/f37b6d5068bffb8d/sifi-merges-with-faes-farma-to-expand-global-access-to-akantior-first-approved-therapy-for-rare-eye-infection 2025-06-11T00:47:07+00:00 hourly 0.9 https://trial.medpath.com/news/2eb85977e49a24de/us-universities-drive-87-of-academic-patents-supporting-fda-drug-approvals-from-2020-2024 2025-06-11T00:47:06+00:00 hourly 0.9 https://trial.medpath.com/news/c49073e83f72fc98/semaglutide-demonstrates-safety-and-efficacy-for-weight-loss-in-schizophrenia-patients 2025-06-11T00:46:54+00:00 hourly 0.9 https://trial.medpath.com/news/9e4164c54a6946b7/nicoya-lifesciences-acquires-applied-photophysics-to-create-integrated-biologics-characterization-platform 2025-06-11T00:46:51+00:00 hourly 0.9 https://trial.medpath.com/news/4cd3996baf1c37e9/subcutaneous-mosunetuzumab-shows-promise-in-untreated-b-cell-lymphomas-with-durable-responses 2025-06-11T00:46:42+00:00 hourly 0.9 https://trial.medpath.com/news/f822356f32374438/bexorg-partners-with-biohaven-to-advance-cns-drug-development-using-ai-driven-whole-brain-discovery-platform 2025-06-11T00:46:31+00:00 hourly 0.9 https://trial.medpath.com/news/09c59ac2ced9a10a/b-cell-depletion-therapy-shows-promise-for-nmosd-treatment-through-comprehensive-immune-system-modulation 2025-06-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8027760148cb4570/green-valley-pharmaceutical-suspends-production-of-controversial-alzheimer-s-drug-gv-971-amid-license-renewal 2025-06-10T21:00:28+00:00 hourly 0.9 https://trial.medpath.com/news/c11b393f779c8215/us-small-molecule-api-cdmo-market-projected-to-reach-12-49-billion-by-2030-driven-by-fda-approvals-and-hpapi-demand 2025-06-10T19:54:08+00:00 hourly 0.9 https://trial.medpath.com/news/0f3d30123cd3a993/nuevocor-receives-fda-ind-clearance-for-gene-therapy-targeting-rare-genetic-heart-disease 2025-06-10T18:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/9698b24d81de9634/fda-manufacturing-issues-delay-unicycive-s-kidney-disease-drug-approval-process 2025-06-10T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/269d5f7b06165931/abbvie-s-skyrizi-and-rinvoq-drive-recovery-as-humira-sales-plummet-50-following-patent-loss 2025-06-10T17:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/19a66d3bc8e7da46/aiml-innovations-secures-provisional-patents-for-ai-powered-ecg-signal-processing-technology 2025-06-10T17:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/f8c3ff867c46f563/astrazeneca-exercises-option-for-quell-s-car-treg-therapy-in-inflammatory-bowel-disease 2025-06-10T17:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/3edf19480fbae884/gyre-therapeutics-initiates-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china 2025-06-10T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/1debb3e1ee5531c6/day-one-biopharmaceuticals-appoints-michael-vasconcelles-as-head-of-r-d-to-drive-pipeline-expansion 2025-06-10T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/7a86276dab0f6fb4/curadev-and-memorial-sloan-kettering-expand-collaboration-to-advance-novel-sting-agonist-crd3874-si 2025-06-10T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/207083b3da426254/32-biosciences-secures-6-million-funding-to-advance-gut-microbiome-diagnostic-and-therapeutic-platform 2025-06-10T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/c9f479a1498f874e/vanda-pharmaceuticals-initiates-first-in-human-trial-of-personalized-aso-therapy-vca-894a-for-ultra-rare-cmt2s 2025-06-10T17:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/3a89bb9c55bee0f2/insmed-s-tpip-achieves-breakthrough-results-in-phase-2b-pah-trial-with-35-reduction-in-pulmonary-vascular-resistance 2025-06-10T17:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/24d12020bca0e7c6/caliway-unveils-cbl-514-preclinical-data-for-glp-1-weight-rebound-prevention-at-bio-2025 2025-06-10T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/7964ac99df1bde23/monte-rosa-therapeutics-receives-fda-clearance-for-mrt-8102-first-nek7-targeted-molecular-glue-degrader-for-inflammatory-diseases 2025-06-10T17:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/710f323991e8edd9/evogene-completes-first-in-class-ai-foundation-model-for-small-molecule-design-with-90-precision 2025-06-10T17:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/905596cc1bcd5ddf/silicogenix-partners-with-bioduro-to-accelerate-ai-driven-drug-discovery-for-complex-diseases 2025-06-10T17:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/b2aa055ab5268818/immvira-initiates-phase-ii-trial-for-novel-oncolytic-immunotherapy-in-bcg-unresponsive-bladder-cancer 2025-06-10T16:16:27+00:00 hourly 0.9 https://trial.medpath.com/news/47e601b7e86dc840/fda-approves-xifyrm-injectable-meloxicam-for-moderate-to-severe-pain-management 2025-06-10T16:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/a754acf95f3ceab8/fda-places-clinical-hold-on-gilead-s-weekly-hiv-combination-therapy-following-safety-signal 2025-06-10T16:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/6f81ec816a79beb3/hellocare-ai-partners-with-mayo-clinic-to-develop-ambient-clinical-intelligence-technology 2025-06-10T16:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/e8157e5158c066d2/antares-therapeutics-launches-with-177-million-series-a-to-advance-first-in-class-cancer-precision-medicines 2025-06-10T14:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/693f0139bb02b496/centauri-therapeutics-demonstrates-novel-immunotherapy-approach-against-multi-drug-resistant-gram-negative-infections 2025-06-10T13:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/3d7ea6931d0d1c35/nhs-becomes-first-european-health-system-to-trial-revolutionary-histotripsy-cancer-treatment 2025-06-10T13:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/375d3e71ddb569b2/tagomics-secures-ps860k-grant-to-develop-novel-multiomics-test-for-early-colorectal-cancer-detection 2025-06-10T13:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/8723043a511e1f04/cellex-expands-gmp-manufacturing-capacity-following-production-of-over-5800-cell-and-gene-therapy-batches 2025-06-10T13:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/512d3e30ff8facd6/cn-bio-expands-fda-recognized-dili-assay-with-cross-species-models-to-improve-drug-safety-predictions 2025-06-10T13:02:46+00:00 hourly 0.9 https://trial.medpath.com/news/592dc3f687256f50/emulate-launches-high-throughput-ava-system-to-replace-animal-testing-in-drug-development 2025-06-10T13:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/8ed63d2f40ac3e62/wuxi-biologics-partners-with-virogen-to-advance-first-in-class-anti-cd3-immunotoxin-vg712-toward-commercial-manufacturing 2025-06-10T13:02:12+00:00 hourly 0.9 https://trial.medpath.com/news/16802bcef147f98a/inflation-reduction-act-to-lower-btk-inhibitor-costs-potentially-transforming-cll-and-mcl-treatment-access 2025-06-10T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/b556e3f1e77e1136/novoviah-s-novoleukintm-platform-achieves-90-sensitivity-in-celiac-disease-detection-through-novel-t-cell-testing 2025-06-10T10:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/fb36863c0a5871a0/uspto-denies-irhythm-patent-challenges-for-vital-signs-monitoring-technology 2025-06-10T08:46:52+00:00 hourly 0.9 https://trial.medpath.com/news/78ad7ddc425b2076/ezz-life-science-secures-21m-distribution-agreement-for-genomic-wellness-products-in-southeast-asia 2025-06-10T08:45:38+00:00 hourly 0.9 https://trial.medpath.com/news/6d15640312137817/smartphone-app-delivers-breakthrough-in-huntington-s-disease-clinical-trial-efficiency 2025-06-10T07:59:28+00:00 hourly 0.9 https://trial.medpath.com/news/d2c12af07491ab41/renaissthera-advances-ai-designed-oral-obesity-drug-targeting-gipr-to-lead-optimization 2025-06-10T06:01:28+00:00 hourly 0.9 https://trial.medpath.com/news/51759ac6b48fca77/alexion-partners-with-pangaea-data-to-develop-ai-system-for-hypophosphatasia-detection 2025-06-10T05:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/10e1e203e663545e/taconic-biosciences-secures-exclusive-crispr-license-from-helmholtz-munich-to-enhance-animal-model-generation 2025-06-10T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/0096480946c8c952/fda-grants-fast-track-designation-to-syntara-s-snt-5505-for-myelofibrosis-treatment 2025-06-10T05:00:03+00:00 hourly 0.9 https://trial.medpath.com/news/e86a19c20e2181ff/macrogenics-secures-70-million-in-zynyz-royalty-deal-extends-cash-runway-through-2027 2025-06-10T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bbf95fce0ed1fb01/phase-ii-trial-of-niraparib-dostarlimab-combination-fails-to-meet-primary-endpoint-in-recurrent-head-and-neck-cancer 2025-06-10T03:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/ec8b98b636c6e983/national-resilience-winds-down-six-manufacturing-facilities-despite-2-25-billion-in-total-funding 2025-06-10T01:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/7ac08f76d1c6a6dc/aribio-and-arcera-forge-600-million-partnership-for-novel-alzheimer-s-drug-ar1001 2025-06-10T01:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/d63c771d1cd38de3/sentio-biosciences-announces-10-6-million-expansion-to-boost-domestic-generic-drug-manufacturing 2025-06-10T01:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/3548e225b44363f1/efgartigimod-shows-promise-in-treating-rare-neurological-autoimmune-disorders-beyond-myasthenia-gravis 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f5cfd9a3a65a37e2/nordic-capital-invests-in-minerva-imaging-to-build-global-radiopharmaceutical-platform 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3a0ca759afcb59e3/cgas-sting-pathway-shows-dual-role-in-breast-cancer-immunotherapy-response 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fd6f53766154e8d1/hanmi-pharmaceutical-to-present-phase-1-results-of-next-generation-obesity-drugs-at-ada-2025 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/56f484b7ae486e86/walmart-launches-healthcare-research-institute-to-expand-clinical-trial-access-and-diversity 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9f589d8e2f456603/resonant-clinical-solutions-names-christophe-berthoux-as-ceo-to-drive-global-expansion 2025-06-09T22:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/97a9bd57ec0d310f/glycovax-pharma-launches-commercial-production-of-affordable-crm197-protein-for-conjugate-vaccines 2025-06-09T22:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/4dfbe1b479f3af24/jaguar-health-reports-statistically-significant-results-in-breast-cancer-subgroup-from-phase-3-ontarget-trial 2025-06-09T21:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/039f254d8d07b749/fda-agrees-vivavision-s-phase-2-trial-can-serve-as-pivotal-study-for-vvn461ld-eye-drop 2025-06-09T21:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/c4e7a85afb265d93/eluminex-biosciences-reports-positive-phase-1b-results-for-novel-pentavalent-antibody-eb-105-in-diabetic-macular-edema 2025-06-09T21:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/e0b795eb13d89f0b/tang-capital-s-concentra-biosciences-acquires-elevation-oncology-for-0-36-per-share-in-latest-biotech-liquidation 2025-06-09T21:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/b676bdd630773cb9/collplant-expands-stemcell-technologies-partnership-to-include-clinical-and-commercial-applications-of-plant-derived-collagen 2025-06-09T21:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/0cc5750e008a3c4a/mannkind-prepares-to-present-pediatric-inhaled-insulin-data-at-ada-scientific-sessions 2025-06-09T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/61fd7d489807dc8c/fda-approves-merck-s-enflonsia-for-rsv-prevention-in-infants-with-single-weight-independent-dose 2025-06-09T20:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/1644a38ed7c6fa1d/real-world-evidence-validates-clinical-trial-outcomes-in-advanced-urothelial-carcinoma-treatment 2025-06-09T20:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/699d6d912cdf899f/psilera-partners-with-hesperos-to-advance-organ-on-a-chip-testing-for-frontotemporal-dementia-drug 2025-06-09T19:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/b94610d624fca5a7/concentra-biosciences-to-acquire-elevation-oncology-for-0-36-per-share-plus-contingent-value-rights 2025-06-09T17:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/8daf6201d829c3a3/scottish-health-authority-rejects-alzheimer-s-drug-donanemab-despite-uk-regulatory-approval 2025-06-09T17:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/421fa9729ceb1f38/aethlon-medical-s-hemopurifier-shows-promise-for-long-covid-treatment-through-extracellular-vesicle-removal 2025-06-09T17:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/e5e2a8491f8fa0d6/electric-fields-combined-with-immunotherapy-show-70-survival-improvement-in-glioblastoma-patients 2025-06-09T17:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/9efc314a6d571481/mosanna-therapeutics-secures-80m-series-a-to-advance-nasal-spray-treatment-for-obstructive-sleep-apnea 2025-06-09T17:12:32+00:00 hourly 0.9 https://trial.medpath.com/news/4c8b7c51d2b4b164/rxmp-therapeutics-advances-hemostatic-agent-rmp-402-with-dod-partnership-and-fda-manufacturing-approval 2025-06-09T17:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/6f3c8a0d8b4862f8/axio-biopharma-and-likarda-form-strategic-partnership-to-integrate-ai-manufacturing-with-advanced-drug-delivery 2025-06-09T17:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/593626700e049f12/gl-chemtec-completes-state-of-the-art-gmp-facility-to-accelerate-clinical-trial-material-production 2025-06-09T17:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/39c9a9d56119cc53/sino-biopharmaceutical-s-tqc3721-inhalation-drug-receives-phase-iii-approval-for-copd-treatment 2025-06-09T17:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/46109aff4adb58fa/neowise-biotechnology-partners-with-beone-medicines-to-advance-ipsc-based-off-the-shelf-cell-therapies 2025-06-09T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/e951b53269351d1b/fable-therapeutics-appoints-former-astrazeneca-executive-david-j-baker-as-chief-scientific-officer 2025-06-09T17:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/585328b56822df25/innospera-pharma-appoints-dr-glenn-crater-as-chief-medical-officer-to-advance-ipf-drug-ing-006 2025-06-09T17:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/ac798b5b82772a28/complement-1-raises-16m-to-scale-ai-powered-cancer-lifestyle-platform-with-90-patient-adherence 2025-06-09T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/bfd4c89d073efd79/olanzapine-shows-promise-in-preventing-radiation-induced-nausea-and-vomiting-in-phase-3-trial 2025-06-09T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/e83d7da63ba59615/beacon-therapeutics-appoints-gene-therapy-veteran-dr-daniel-chung-as-chief-medical-officer 2025-06-09T17:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/2ae9bfc41851b963/citius-oncology-partners-with-cardinal-health-for-lymphir-distribution-ahead-of-commercial-launch 2025-06-09T17:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/8bea2365d076b308/tybr-health-secures-fda-510-k-clearance-for-b3-gel-system-to-protect-healing-tissues-in-musculoskeletal-surgery 2025-06-09T17:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/1dfa285cf2ddd341/avanzanite-partners-with-agios-to-commercialize-first-in-class-pyruvate-kinase-activator-across-europe 2025-06-09T17:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/8d35d6c96fb88c23/world-s-first-hla-g-targeted-exosome-therapy-sob100-receives-fda-approval-for-phase-i-cancer-trials 2025-06-09T16:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/b680e4e514ae9fc0/circuit-clinical-and-lightship-merge-to-transform-clinical-trial-access-and-delivery 2025-06-09T16:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/d8b74824cceb4834/single-cell-analysis-reveals-brca1-mutation-drives-distinct-tumor-microenvironments-in-triple-negative-breast-cancer 2025-06-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a298abdfc689e82f/genetic-factors-drive-early-b-cell-repletion-after-anti-cd20-therapy-in-african-american-ms-patients 2025-06-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6dfd258dd077fed5/wuxi-biologics-breaks-ground-on-china-s-first-dual-chamber-lyophilization-manufacturing-site-in-chengdu 2025-06-09T15:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/5b304bfae2b3d542/nivolumab-plus-chemotherapy-demonstrates-five-year-survival-benefit-in-resectable-nsclc 2025-06-09T14:59:41+00:00 hourly 0.9 https://trial.medpath.com/news/ac5ee2daef0a777f/novel-therapeutic-classes-transform-future-treatment-paradigm-for-metastatic-castration-resistant-prostate-cancer 2025-06-09T13:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/c77291858a5ef2e9/lipocine-s-partner-files-new-drug-submission-for-tlando-in-canada-targeting-700000-annual-trt-prescriptions 2025-06-09T13:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/a4a6f45da30bb506/university-of-arizona-researchers-identify-drug-candidate-that-reverses-heart-failure-progression-in-mouse-models 2025-06-09T13:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/5908f738dc94ae34/nutriband-secures-new-u-s-patent-for-aversa-abuse-deterrent-transdermal-technology 2025-06-09T13:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/54103c12f4328603/metsera-s-met-233i-achieves-8-4-weight-loss-in-phase-1-trial-enabling-first-monthly-amylin-glp-1-combination 2025-06-09T13:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/9e5838b094f2a839/secura-bio-initiates-phase-3-terzo-trial-of-copiktra-for-rare-t-cell-lymphoma 2025-06-09T13:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/5997bdc4766f7eb0/seed-therapeutics-appoints-dr-bill-desmarais-as-cfo-and-cbo-to-advance-targeted-protein-degradation-pipeline 2025-06-09T13:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/254cd59fc0396fad/anlotinib-plus-immune-checkpoint-inhibitors-shows-promise-in-previously-treated-extensive-stage-small-cell-lung-cancer 2025-06-09T13:01:40+00:00 hourly 0.9 https://trial.medpath.com/news/3296f939e5031312/oxford-and-recibiopharm-expand-malaria-vaccine-partnership-to-advance-two-blood-stage-candidates 2025-06-09T13:00:46+00:00 hourly 0.9 https://trial.medpath.com/news/4db26ab1de2a44a4/ionq-achieves-20-fold-speedup-in-drug-discovery-simulations-through-quantum-classical-hybrid-computing 2025-06-09T13:00:44+00:00 hourly 0.9 https://trial.medpath.com/news/bb95347b58b6b667/ema-reviews-chickenpox-vaccines-after-fatal-encephalitis-case-in-polish-child 2025-06-09T12:59:31+00:00 hourly 0.9 https://trial.medpath.com/news/eccf204f400946db/fda-rejects-axsome-s-fibromyalgia-drug-application-due-to-trial-design-issues 2025-06-09T12:58:35+00:00 hourly 0.9 https://trial.medpath.com/news/dc61db833d314bef/fda-approves-first-triple-combination-hypertension-drug-widaplik-for-initial-treatment 2025-06-09T12:58:33+00:00 hourly 0.9 https://trial.medpath.com/news/a73e04328d5d5deb/statins-show-39-mortality-reduction-in-sepsis-patients-large-study-reveals 2025-06-09T12:58:27+00:00 hourly 0.9 https://trial.medpath.com/news/f673f7d7f0080de7/merck-s-enlicitide-shows-promise-as-first-oral-pcsk9-inhibitor-in-phase-3-trials 2025-06-09T12:58:23+00:00 hourly 0.9 https://trial.medpath.com/news/465baac32e602bef/metsera-s-monthly-amylin-injection-achieves-8-4-weight-loss-in-phase-i-trial 2025-06-09T12:58:17+00:00 hourly 0.9 https://trial.medpath.com/news/36ca0be9e4b03d18/glenmark-pharmaceuticals-receives-dcgi-approval-to-launch-brukinsa-for-five-b-cell-malignancies-in-india 2025-06-09T08:58:28+00:00 hourly 0.9 https://trial.medpath.com/news/b1fa260ebfdbec7d/everest-medicines-reports-promising-phase-1b-2a-results-for-ever001-btk-inhibitor-in-primary-membranous-nephropathy 2025-06-09T08:57:54+00:00 hourly 0.9 https://trial.medpath.com/news/a52c15490432b7e0/ema-extends-shelf-life-of-veterinary-cancer-drug-masivet-to-48-months 2025-06-09T08:57:50+00:00 hourly 0.9 https://trial.medpath.com/news/9d85dc208f906883/advent-international-invests-175-million-in-animal-health-generics-company-felix-pharmaceuticals 2025-06-09T08:57:46+00:00 hourly 0.9 https://trial.medpath.com/news/b6cd6c65f0c04c29/philippines-fda-expands-vat-free-medicine-list-to-include-new-cancer-diabetes-and-cardiovascular-treatments 2025-06-09T05:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/22fd3537024670a3/otsuka-pharmaceutical-challenges-vera-therapeutics-in-kidney-disease-race-as-glp-1-drugs-face-eye-safety-scrutiny 2025-06-09T05:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/b7d4006bd24d49bd/samsung-bioepis-partners-with-nipro-to-commercialize-biosimilars-in-japan-including-ustekinumab-candidate 2025-06-09T02:56:46+00:00 hourly 0.9 https://trial.medpath.com/news/728cea4076033a56/chronic-gvhd-treatment-evolution-biomarker-guided-therapy-and-steroid-free-approaches-show-promise 2025-06-09T02:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/ac684d113059142c/revolutionary-gene-therapy-and-bbb-penetrating-treatments-transform-hunter-syndrome-treatment-landscape 2025-06-08T22:00:45+00:00 hourly 0.9 https://trial.medpath.com/news/09f5ff5b857bcb78/four-promising-gene-and-cell-therapies-challenge-aldurazyme-s-dominance-in-mps-i-treatment 2025-06-08T20:59:58+00:00 hourly 0.9 https://trial.medpath.com/news/9daeeb1970644a5b/chugai-pharmaceutical-eyes-combination-therapy-to-set-new-standard-for-obesity-treatment 2025-06-08T13:46:28+00:00 hourly 0.9 https://trial.medpath.com/news/fdb758d4e4a9d82c/carboplatin-addition-to-standard-chemotherapy-shows-no-survival-benefit-in-triple-negative-breast-cancer 2025-06-08T08:45:09+00:00 hourly 0.9 https://trial.medpath.com/news/e1cf32243559357e/uk-doctors-trial-freeze-dried-fecal-microbiota-pills-to-combat-antibiotic-resistant-superbugs 2025-06-08T04:47:02+00:00 hourly 0.9 https://trial.medpath.com/news/3cd99e67db72f8fa/researchers-identify-two-drug-candidates-for-ultra-rare-x-linked-myopathy-using-zebrafish-model 2025-06-08T04:46:39+00:00 hourly 0.9 https://trial.medpath.com/news/2ee1ea7e87b116c3/fda-rejects-elamipretide-for-rare-mitochondrial-disease-despite-patient-improvements 2025-06-08T00:59:03+00:00 hourly 0.9 https://trial.medpath.com/news/f2139e2cce98984e/new-zealand-universities-launch-clinical-trials-testing-psychedelics-for-treatment-resistant-mental-health-disorders 2025-06-07T22:58:32+00:00 hourly 0.9 https://trial.medpath.com/news/e63778b922ee3e9f/uc-berkeley-awards-200000-venture-grant-to-hypo2regen-therapeutics-with-future-investment-option 2025-06-07T21:01:51+00:00 hourly 0.9 https://trial.medpath.com/news/27c33203e9ae2b16/serve-you-rx-adds-two-ustekinumab-biosimilars-to-formulary-offering-up-to-96-cost-savings 2025-06-07T18:59:46+00:00 hourly 0.9 https://trial.medpath.com/news/7febb7c7eecd69cd/empagliflozin-demonstrates-kidney-safety-across-multiple-patient-populations-new-pooled-analysis-shows 2025-06-07T17:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/6c50faa4a0d53782/il-12-modified-mrna-vaccines-demonstrate-enhanced-t-cell-activation-in-university-of-pennsylvania-study 2025-06-07T16:49:13+00:00 hourly 0.9 https://trial.medpath.com/news/0175c9dc7f457b99/fda-approves-moderna-s-next-generation-covid-19-vaccine-mrna-1283-with-enhanced-efficacy 2025-06-07T16:45:53+00:00 hourly 0.9 https://trial.medpath.com/news/8ce986f69fa268df/zhengye-biotechnology-completes-6-million-ipo-as-chinese-veterinary-vaccine-manufacturer-enters-us-markets 2025-06-07T15:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/bf0aafdb659164fa/achieve-trial-shows-spironolactone-fails-to-reduce-cardiovascular-risk-in-dialysis-patients 2025-06-07T13:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/c9d10e0e03a79eeb/india-s-5000-crore-prip-scheme-signals-major-shift-from-generic-manufacturing-to-innovation-led-pharma-growth 2025-06-07T12:46:45+00:00 hourly 0.9 https://trial.medpath.com/news/80ec1e2b5b832c18/new-screening-algorithms-and-diagnostic-approaches-aim-to-reduce-pulmonary-arterial-hypertension-detection-delays 2025-06-07T12:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/6fa72a26cf0b2034/health-canada-approves-first-of-its-kind-antibody-drug-conjugate-for-multiple-myeloma-treatment 2025-06-07T09:00:22+00:00 hourly 0.9 https://trial.medpath.com/news/b9052861c268b2a0/new-study-raises-safety-concerns-about-fecal-microbiota-transplants 2025-06-07T08:59:26+00:00 hourly 0.9 https://trial.medpath.com/news/63469110319d9291/uconn-researchers-develop-novel-nanoparticle-mrna-vaccine-platform-for-infectious-bronchitis-virus-in-poultry 2025-06-07T04:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/e701945b8f7205f1/pharmacist-led-interventions-generate-9-million-in-cancer-care-cost-savings-through-remote-clinical-reviews 2025-06-07T03:00:15+00:00 hourly 0.9 https://trial.medpath.com/news/77f8f742c0b8c766/acip-members-face-termination-as-rfk-jr-s-vaccine-policy-changes-spark-institutional-upheaval 2025-06-07T02:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/130c70c7fbd59175/high-placebo-response-rates-challenge-lupus-drug-development-as-researchers-develop-new-trial-strategies 2025-06-07T02:59:34+00:00 hourly 0.9 https://trial.medpath.com/news/49e8f6fe7947729f/mission-bio-secures-funding-to-advance-single-cell-tri-omics-platform-for-cancer-drug-development 2025-06-07T02:59:26+00:00 hourly 0.9 https://trial.medpath.com/news/927fc91f515a0360/first-ascent-biomedical-partners-with-fight-colorectal-cancer-for-350000-precision-medicine-study 2025-06-07T01:59:20+00:00 hourly 0.9 https://trial.medpath.com/news/3e8b5f905a4fb551/church-dwight-recalls-zicam-and-orajel-nasal-swabs-due-to-fungal-contamination-risk 2025-06-07T01:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/0c6e18c60a8d2597/neoadjuvant-immunotherapy-plus-chemotherapy-improves-long-term-survival-in-operable-nsclc 2025-06-07T01:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/f0aeee4381c69b42/powers-health-partners-with-profound-research-to-establish-clinical-research-center-in-northwest-indiana 2025-06-07T00:57:54+00:00 hourly 0.9 https://trial.medpath.com/news/676f368c170a47a7/novartis-raises-mid-term-sales-outlook-to-6-growth-through-2029-on-pipeline-strength 2025-06-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8e371cc4e5aaa31b/nkarta-appoints-immunology-expert-shawn-rose-as-chief-medical-officer-to-lead-autoimmune-nk-cell-therapy-development 2025-06-06T20:50:23+00:00 hourly 0.9 https://trial.medpath.com/news/473cd6c8f4ebabaa/brenntag-specialties-acquires-czech-firm-mcepharma-to-expand-gmp-capabilities-across-emea-region 2025-06-06T20:50:21+00:00 hourly 0.9 https://trial.medpath.com/news/408e4fa8af664178/trump-administration-cancels-766-million-mrna-bird-flu-vaccine-contract-with-moderna 2025-06-06T20:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/0831a9dbde778e0e/federal-circuit-transfers-66-million-patent-dispute-between-alkermes-and-acorda-therapeutics 2025-06-06T20:48:56+00:00 hourly 0.9 https://trial.medpath.com/news/f7bb3bd32732f7fc/bionet-and-bio-farma-partner-to-accelerate-tdap-vaccine-access-across-southeast-asia 2025-06-06T20:48:30+00:00 hourly 0.9 https://trial.medpath.com/news/00d4beef44e2114e/major-pbms-exclude-humira-biosimilars-from-2025-formularies-favor-private-label-products 2025-06-06T20:47:39+00:00 hourly 0.9 https://trial.medpath.com/news/fea12af2e0ad7262/fda-accepts-kura-oncology-s-nda-for-ziftomenib-in-npm1-mutant-aml-with-priority-review 2025-06-06T20:47:35+00:00 hourly 0.9 https://trial.medpath.com/news/c9dafa6c00d4edc3/ai-integration-and-advanced-drug-delivery-systems-reshape-pharmaceutical-outsourcing-models 2025-06-06T20:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/3fd2d40cdd3b3cab/transcatheter-pda-closure-shows-comparable-respiratory-outcomes-to-surgery-in-preterm-infants 2025-06-06T20:46:38+00:00 hourly 0.9 https://trial.medpath.com/news/f6ab2572b6b37d05/fda-grants-phathom-pharmaceuticals-10-year-market-exclusivity-for-voquezna-through-2032 2025-06-06T20:46:34+00:00 hourly 0.9 https://trial.medpath.com/news/22cff01d98f27b0d/kelun-biotech-raises-250-million-in-largest-hong-kong-biopharma-follow-on-offering-in-12-months 2025-06-06T19:59:25+00:00 hourly 0.9 https://trial.medpath.com/news/cba4d2948346e771/otsuka-s-sibeprenlimab-achieves-51-reduction-in-proteinuria-for-iga-nephropathy-intensifying-competition-with-vera-therapeutics 2025-06-06T18:58:15+00:00 hourly 0.9 https://trial.medpath.com/news/61b856db832e039a/fidaxomicin-demonstrates-superior-efficacy-in-reducing-c-difficile-recurrence-among-high-risk-patients 2025-06-06T17:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/9d68dccafd7c22f1/novo-nordisk-to-present-phase-3-hemophilia-trial-data-at-isth-2025-congress 2025-06-06T17:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/59aea104338e0392/mckesson-corporation-completes-acquisition-of-florida-cancer-specialists-to-strengthen-community-oncology-network 2025-06-06T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/7eddf7b143fb003f/candel-therapeutics-strengthens-board-with-industry-veteran-ahead-of-key-bla-submission 2025-06-06T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/41afd8f077264906/pci-pharma-services-unveils-advanced-sterile-manufacturing-facility-to-boost-biologic-production-capacity 2025-06-06T17:02:16+00:00 hourly 0.9 https://trial.medpath.com/news/6fa81dcf5c81882f/mit-and-recursion-release-boltz-2-open-source-ai-model-achieves-1000x-speed-boost-in-drug-discovery-screening 2025-06-06T17:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/e9a801c52a188d7d/vivoryon-s-varoglutamstat-shows-sustained-kidney-function-improvement-in-phase-2-meta-analysis 2025-06-06T17:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/3aa84dc54cf890e5/aytu-biopharma-secures-exclusive-rights-to-first-in-class-antidepressant-exxua-for-22b-us-market 2025-06-06T17:00:41+00:00 hourly 0.9 https://trial.medpath.com/news/e45c49cd041a96e9/aytu-biopharma-raises-16-6m-to-launch-first-in-class-depression-treatment-exxua 2025-06-06T16:59:27+00:00 hourly 0.9 https://trial.medpath.com/news/9f9e71b833b09465/nemluvio-shows-sustained-long-term-efficacy-in-atopic-dermatitis-with-two-year-extension-data 2025-06-06T13:01:17+00:00 hourly 0.9 https://trial.medpath.com/news/d30a9ab8b02c4788/denovo-biopharma-forms-neuroscience-advisory-board-to-advance-precision-medicine-approach-for-treatment-resistant-depression 2025-06-06T13:00:37+00:00 hourly 0.9 https://trial.medpath.com/news/a540833dba35d621/glycomimetics-stockholders-approve-merger-with-crescent-biopharma-creating-new-oncology-focused-entity 2025-06-06T13:00:28+00:00 hourly 0.9 https://trial.medpath.com/news/5fd4d1ae8bdee0fd/china-s-biopharma-sector-showcases-innovation-leadership-at-bioseedin-2025-conference 2025-06-06T12:59:47+00:00 hourly 0.9 https://trial.medpath.com/news/8ae7136415483e02/htl-biotechnology-launches-eur12-million-sterile-hyaluronic-acid-production-line-to-enable-heat-sensitive-drug-combinations 2025-06-06T12:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/2821ea6a25e76f73/geneditbio-doses-first-patient-in-world-s-first-in-vivo-crispr-trial-for-tgfbi-corneal-dystrophy 2025-06-06T12:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/d9c4778f951988b5/immune-thrombocytopenia-presents-diagnostic-challenges-with-unpredictable-disease-course 2025-06-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bee1061ad732b12a/bitbiome-partners-with-leading-cmo-to-enable-large-scale-biomanufacturing-of-microbial-derived-products 2025-06-06T11:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/b2caf9f4aeb51f53/pyx-health-acquires-farmboxrx-in-47-5m-deal-to-combat-health-disparities-through-food-based-care 2025-06-06T09:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/148714ed8093bdf9/hemispherian-s-glix1-receives-ema-orphan-drug-designation-for-glioma-treatment 2025-06-06T09:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/1ee35efc7722b486/penumbra-launches-ruby-xl-system-the-largest-embolization-coil-platform-for-vascular-procedures 2025-06-06T09:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/b10ff9463fc10104/elgan-pharma-and-chiesi-begin-phase-3-trial-of-elgn-2112-for-intestinal-malabsorption-in-preterm-infants 2025-06-06T09:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/08f27776677fe718/improved-pharma-completes-fifth-expansion-at-kurz-purdue-technology-center-now-occupying-over-5500-square-feet 2025-06-06T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1efcabe6f232469f/abl-bio-receives-regulatory-approval-for-triple-combination-cancer-therapy-trial 2025-06-06T07:00:06+00:00 hourly 0.9 https://trial.medpath.com/news/91e0de54b9de54b1/abilitypharma-s-ibrilatazar-doubles-overall-survival-in-squamous-non-small-cell-lung-cancer-trial 2025-06-06T05:58:12+00:00 hourly 0.9 https://trial.medpath.com/news/b8403ebe64a644c4/foldax-receives-world-s-first-approval-for-polymer-heart-valve-in-india 2025-06-06T04:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/9e9e69cdbc645248/long-acting-injectable-antipsychotics-proposed-as-new-standard-of-care-for-schizophrenia-treatment 2025-06-06T04:58:54+00:00 hourly 0.9 https://trial.medpath.com/news/ce97edacd82479c6/prophase-labs-forms-clinical-advisory-board-to-advance-be-smart-esophageal-cancer-diagnostic-platform 2025-06-06T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/90ab8247f19893d1/seyltx-advances-chronic-cough-pipeline-with-optimized-ifenprodil-dosing-and-strategic-neurop-partnership 2025-06-06T03:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/81153c2024cfc271/insurance-prior-authorization-delays-cancer-treatment-by-up-to-two-weeks-forcing-suboptimal-care-decisions 2025-06-06T03:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/939fb1907ff44208/hengrui-pharma-presents-72-studies-at-asco-2025-demonstrating-broad-oncology-pipeline-impact 2025-06-06T03:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/3c3431bdc9136989/adolescent-obesity-medication-prescriptions-surge-301-despite-persistent-access-barriers 2025-06-06T02:01:38+00:00 hourly 0.9 https://trial.medpath.com/news/e39182f88799c633/impact-biotech-s-padeliporfin-vtp-therapy-enables-surgical-resection-in-previously-inoperable-pancreatic-cancer-patient 2025-06-06T00:51:32+00:00 hourly 0.9 https://trial.medpath.com/news/8a708d63394130ce/roche-s-tecentriq-cuts-colon-cancer-recurrence-by-50-in-patients-with-dna-repair-defects 2025-06-06T00:50:16+00:00 hourly 0.9 https://trial.medpath.com/news/aea71cffe5184f54/lenacapavir-shows-100-efficacy-in-hiv-prevention-with-twice-yearly-injection 2025-06-06T00:49:59+00:00 hourly 0.9 https://trial.medpath.com/news/8a15820ff7fe46b1/zeiss-clarus-700-ultra-widefield-retinal-imaging-system-receives-nmpa-approval-in-china 2025-06-06T00:49:20+00:00 hourly 0.9 https://trial.medpath.com/news/5d14c3d6c2b33fec/signify-bio-launches-with-15m-funding-to-develop-in-situ-protein-therapeutics-platform 2025-06-06T00:47:54+00:00 hourly 0.9 https://trial.medpath.com/news/d033dc2315028217/fda-grants-gras-clearance-for-omniactive-s-lutemax-free-lutein-in-infant-formula 2025-06-06T00:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/655d43ab7d111ffe/inka-health-launches-global-ai-oncology-consortium-to-advance-predictive-cancer-research 2025-06-06T00:47:16+00:00 hourly 0.9 https://trial.medpath.com/news/e93e7acfa88caf8e/bytebrain-launches-medrail-ai-platform-to-transform-clinical-trial-operations 2025-06-06T00:46:07+00:00 hourly 0.9 https://trial.medpath.com/news/f3fb59b9b0c17192/iovance-biotherapeutics-faces-major-setback-as-cell-therapy-amtagvi-commercial-launch-struggles 2025-06-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4fccc68f104d96df/humacyte-s-bioengineered-vessel-shows-superior-performance-in-high-risk-dialysis-patients 2025-06-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/084d1739fa0401ce/fda-clears-medtronic-s-enhanced-visualase-v2-mri-guided-laser-ablation-system-for-brain-surgery 2025-06-05T23:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/2403f888a286d201/p2y12-inhibitors-show-23-reduction-in-cardiovascular-events-compared-to-aspirin-in-post-stent-patients 2025-06-05T22:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/b9c714cd1e762f0e/fda-launches-ai-tool-elsa-for-drug-reviews-while-novo-nordisk-struggles-in-obesity-market-competition 2025-06-05T22:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/e497234351b50794/first-clinical-trial-shows-nicotinamide-riboside-improves-multiple-health-outcomes-in-werner-syndrome-patients 2025-06-05T22:02:34+00:00 hourly 0.9 https://trial.medpath.com/news/92a1fb05db892b6b/nrg-oncology-trial-shows-regional-nodal-radiation-provides-no-benefit-for-breast-cancer-patients-with-node-conversion-after-neoadjuvant-chemotherapy 2025-06-05T22:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/b918ae3a7eebb69c/japanese-study-shows-81-success-rate-for-pfo-closure-in-drug-resistant-migraine-patients 2025-06-05T21:02:40+00:00 hourly 0.9 https://trial.medpath.com/news/07ff33ec18b3dbbf/kennedy-pledges-accelerated-fda-approvals-for-rare-disease-therapies-to-maintain-us-biotech-leadership 2025-06-05T20:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/df8f71c9682acf40/plt-health-solutions-serezin-shows-significant-sleep-and-pain-relief-benefits-in-clinical-trial 2025-06-05T20:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/269d3db2d4ed8d57/cns-pharmaceuticals-presents-brain-penetrating-taxane-tpi-287-for-glioblastoma-treatment-at-2025-brain-tumor-summit 2025-06-05T20:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/a9ea3d9710f29605/artelo-s-fabp5-inhibitor-art26-12-shows-comparable-efficacy-to-naproxen-in-osteoarthritis-pain-study 2025-06-05T19:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/0414d4d064f34898/dr-elizabeth-mittendorf-outlines-vision-as-asco-president-elect-to-advance-multidisciplinary-cancer-care-and-workforce-support 2025-06-05T17:57:53+00:00 hourly 0.9 https://trial.medpath.com/news/e0460df1a1705ec7/upstream-bio-presents-data-showing-verekitug-s-superior-potency-through-tslp-receptor-targeting-at-eaaci-congress 2025-06-05T17:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/097f1dfa0227d197/valneva-s-chikungunya-vaccine-shows-sustained-antibody-response-in-children-after-six-months 2025-06-05T17:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/91679a5e564d7036/casma-therapeutics-nominates-first-in-class-trpml1-agonist-csm-101-for-parkinson-s-disease-treatment 2025-06-05T17:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/5e7b8862d7174233/qurebio-secures-14-million-series-c1-funding-to-advance-bispecific-antibody-pipeline 2025-06-05T17:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/2fd3c778c284e369/allay-therapeutics-secures-57-5m-series-d-to-advance-ultra-sustained-pain-management-platform 2025-06-05T17:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/50f4fe8c93fa44ae/linear-diagnostics-secures-ps1m-to-advance-5-minute-sti-diagnostic-test 2025-06-05T17:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/2811a086c607efb1/mandatory-human-abuse-liability-assessment-reshapes-drug-development-strategy-and-regulatory-compliance 2025-06-05T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/4e3ec9c5ae9e9d00/iperionx-secures-99m-defense-contract-for-domestic-titanium-manufacturing 2025-06-05T17:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/dfdaf06480da6982/veongen-therapeutics-receives-fda-rare-pediatric-disease-designation-for-stargardt-disease-gene-therapy-vg801 2025-06-05T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/e80f78608f775b18/scinai-immunotherapeutics-surges-104-following-italian-regulatory-clearance-for-pincell-acquisition 2025-06-05T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/c09651d2ab3c442a/uk-drug-regulator-issues-first-contraception-warning-for-weight-loss-injections-after-40-pregnancy-reports 2025-06-05T17:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/53f7b37f79d8bc56/immunoprecise-achieves-ai-driven-breakthrough-in-universal-dengue-vaccine-discovery 2025-06-05T17:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/0e42d3fd90324883/cresemba-antifungal-drug-achieves-record-global-sales-triggers-2-5m-milestone-payment-to-basilea 2025-06-05T15:00:54+00:00 hourly 0.9 https://trial.medpath.com/news/5339849c37cf9efa/osivax-completes-phase-2a-booster-trial-for-broad-spectrum-influenza-vaccine-ovx836 2025-06-05T14:59:10+00:00 hourly 0.9 https://trial.medpath.com/news/9473cbf5bbb95f2f/cellectar-biosciences-raises-2-5-million-through-warrant-exercise-to-advance-cancer-drug-development 2025-06-05T14:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/fe020cd6b93f4e46/cancervax-achieves-breakthrough-in-targeted-nanoparticle-development-for-universal-cancer-treatment 2025-06-05T12:50:22+00:00 hourly 0.9 https://trial.medpath.com/news/88451e97d1b7dbd0/biocytogen-secures-japan-patent-for-renmab-platform-strengthening-global-ip-portfolio-for-fully-human-antibody-discovery 2025-06-05T12:49:19+00:00 hourly 0.9 https://trial.medpath.com/news/cd643b0a8e6a5e69/harmony-biosciences-secures-patent-protection-for-wakix-through-2030-settlement-with-lupin 2025-06-05T12:49:17+00:00 hourly 0.9 https://trial.medpath.com/news/e1c65abf1bf88e87/mitochondrial-dna-variant-predicts-immunotherapy-resistance-in-metastatic-melanoma 2025-06-05T12:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/8139cbafde562007/mediar-therapeutics-initiates-phase-2-trial-of-first-in-class-anti-wisp1-antibody-for-idiopathic-pulmonary-fibrosis 2025-06-05T12:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/6f58e3b1ec8a67a0/kiniksa-pharmaceuticals-advances-kpl-387-phase-2-3-trial-for-recurrent-pericarditis 2025-06-05T12:47:54+00:00 hourly 0.9 https://trial.medpath.com/news/18603734940962da/juvenescence-acquires-ai-drug-discovery-company-ro5-to-accelerate-age-related-disease-pipeline 2025-06-05T12:45:29+00:00 hourly 0.9 https://trial.medpath.com/news/a01065cdcffbdac1/confidence-study-shows-superior-kidney-protection-with-combined-finerenone-and-sglt-2-inhibitor-therapy 2025-06-05T12:44:48+00:00 hourly 0.9 https://trial.medpath.com/news/c4ccbd78e31663f5/kiora-pharmaceuticals-partners-with-senju-for-kio-301-development-in-asian-markets-worth-over-110-million 2025-06-05T12:44:45+00:00 hourly 0.9 https://trial.medpath.com/news/495108d6cdaa8c45/bnt327-pm8002-bispecific-antibody-shows-promising-activity-in-unresectable-mesothelioma 2025-06-05T12:44:26+00:00 hourly 0.9 https://trial.medpath.com/news/ce73603ece3f50cd/ocugen-secures-161m-gene-therapy-licensing-deal-for-ocu400-in-korean-market 2025-06-05T12:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/418e0dd0d2d63e6f/servier-india-launches-first-in-class-idh1-targeted-therapy-ivosidenib-for-rare-blood-and-bile-duct-cancers 2025-06-05T12:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/df3f7488b7ad21d1/fda-approves-hundreds-of-drugs-without-adequate-evidence-of-effectiveness-investigation-reveals 2025-06-05T12:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/15b9a155214d5c76/swiss-researchers-pioneer-multiomics-based-cancer-treatment-predictions-in-first-of-kind-clinical-study 2025-06-05T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/b8ed1d67d45fdef3/fujirebio-partners-with-stanford-medicine-to-advance-ultrasensitive-infectious-disease-diagnostics 2025-06-05T10:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/059322a29cf28109/clarity-pharmaceuticals-64cu-sartate-shows-superior-lesion-detection-in-phase-ii-disco-trial-for-neuroendocrine-tumors 2025-06-05T10:00:16+00:00 hourly 0.9 https://trial.medpath.com/news/560764e6bbc0ca7a/cullinan-therapeutics-licenses-bcma-targeted-bispecific-t-cell-engager-for-autoimmune-disease-development 2025-06-05T09:59:08+00:00 hourly 0.9 https://trial.medpath.com/news/def053d3aeaea3b5/oncolytic-virus-cancer-therapy-pipeline-shows-strong-growth-with-120-companies-developing-125-treatments 2025-06-05T09:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/b22aaa2732bdba08/kancera-receives-fda-fast-track-eligibility-for-kand567-in-heart-attack-treatment 2025-06-05T08:58:50+00:00 hourly 0.9 https://trial.medpath.com/news/83edc3ba839a0f85/dr-reddy-s-and-alvotech-partner-to-develop-keytruda-biosimilar-in-29-5-billion-market 2025-06-05T08:58:16+00:00 hourly 0.9 https://trial.medpath.com/news/552c55ccd489b362/mgi-tech-expands-partnership-with-brazil-s-fiocruz-to-enhance-genetic-sequencing-for-cancer-and-infectious-disease-diagnostics 2025-06-05T08:11:57+00:00 hourly 0.9 https://trial.medpath.com/news/145a12abcd1d36e7/melbourne-researchers-develop-mrna-technology-to-force-hiv-out-of-cellular-hiding-places 2025-06-05T08:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/c26ed126b05e2e24/formycon-s-ranivisio-becomes-first-lucentis-biosimilar-approved-in-brazil 2025-06-05T08:11:50+00:00 hourly 0.9 https://trial.medpath.com/news/0e6873aae9f43d95/astrivax-therapeutics-launches-phase-i-trial-of-avx70371-hepatitis-b-immunotherapy 2025-06-05T08:11:46+00:00 hourly 0.9 https://trial.medpath.com/news/3a87753e5f5639bd/livanova-s-core-vns-study-demonstrates-sustained-seizure-reduction-in-drug-resistant-epilepsy-patients 2025-06-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/88f6774c05d82eae/metsera-to-showcase-next-generation-obesity-therapies-at-ada-2025-with-clinical-data-from-ultra-long-acting-glp-1-agonist 2025-06-05T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/2ae5e2e414aaef8f/comprehensive-analysis-of-methotrexate-safety-profile-reveals-gender-and-age-specific-adverse-event-patterns 2025-06-05T07:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/a34e881d989e5441/unf-researchers-advance-cancer-fighting-compound-to-animal-trials-after-breakthrough-discovery 2025-06-05T06:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/e6e0bb7d1511fb6b/acerand-therapeutics-initiates-first-in-human-trial-of-novel-cyp11a1-inhibitor-ace-232-for-advanced-prostate-cancer 2025-06-05T05:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/6079fa7aa209daed/openwater-s-portable-stroke-detection-device-shows-promise-in-field-diagnostics-and-rehabilitation-research 2025-06-05T05:03:34+00:00 hourly 0.9 https://trial.medpath.com/news/411e9121a0c4dc63/fda-denies-approval-for-elamipretide-forcing-stealth-biotherapeutics-to-halt-production-of-rare-disease-treatment 2025-06-05T05:03:28+00:00 hourly 0.9 https://trial.medpath.com/news/d786fe70604840a0/tivozanib-monotherapy-shows-promise-as-second-line-treatment-for-metastatic-rcc-following-contemporary-immunotherapy 2025-06-05T05:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/0f5cd31451ae78fc/terthera-launches-world-s-first-gmp-compliant-terbium-161-for-enhanced-cancer-radiotherapy 2025-06-05T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/1d4805f4cb8aea18/mallia-completes-eur5-5m-seed-funding-to-advance-scd83-based-hair-loss-treatments 2025-06-05T03:57:08+00:00 hourly 0.9 https://trial.medpath.com/news/c0fda68118ddf9be/rakuten-medical-secures-amed-funding-for-novel-pd-l1-photoimmunotherapy-rm-0256 2025-06-05T03:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/b2259fb071aeb3c3/nucleus-genomics-launches-first-genetic-optimization-software-for-ivf-embryo-selection 2025-06-05T03:00:07+00:00 hourly 0.9 https://trial.medpath.com/news/cab19ae74ae438f1/machine-learning-model-outperforms-individual-biomarkers-in-predicting-advanced-renal-cell-carcinoma-treatment-response 2025-06-05T02:58:32+00:00 hourly 0.9 https://trial.medpath.com/news/37953b1b74555ba8/ret-inhibitor-rechallenge-shows-promise-in-pre-treated-nsclc-patients-after-toxicity-related-discontinuation 2025-06-05T01:57:16+00:00 hourly 0.9 https://trial.medpath.com/news/537a407761c93e62/mycovia-pharmaceuticals-initiates-phase-2-trial-of-oteseconazole-for-cryptococcal-meningitis 2025-06-05T01:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/48b925eca79b7a57/toyobo-and-dmc-biotechnologies-partner-to-develop-sustainable-chemical-intermediates-through-precision-fermentation 2025-06-05T01:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/73533ad79af047f4/zigakibart-shows-sustained-60-proteinuria-reduction-in-100-week-iga-nephropathy-study 2025-06-05T01:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/3be4ed6b2758b844/stanford-researchers-develop-milli-spinner-technology-that-doubles-blood-clot-removal-effectiveness 2025-06-05T01:01:20+00:00 hourly 0.9 https://trial.medpath.com/news/c16fcd3feb94aa56/ai-breakthrough-accelerates-protein-engineering-for-next-generation-therapeutics 2025-06-05T00:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/8ea7ebb898c48c94/knight-therapeutics-acquires-sumitomo-s-canadian-portfolio-including-myfembree-and-orgovyx-for-c-25-4-million 2025-06-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bdeea9a3d34cc46b/bnt113-cancer-vaccine-shows-promise-in-phase-ii-iii-trial-for-hpv16-head-and-neck-cancer 2025-06-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/22b64078557edcd4/highridge-medical-divests-bone-healing-division-to-focus-on-core-spine-technologies 2025-06-04T23:58:16+00:00 hourly 0.9 https://trial.medpath.com/news/2a5c9c0f395bb361/trisalus-launches-enhanced-trinav-flx-infusion-system-for-improved-tumor-drug-delivery 2025-06-04T23:55:45+00:00 hourly 0.9 https://trial.medpath.com/news/6308a9f81235b6e0/fresenius-medical-care-advances-u-s-rollout-of-high-volume-hemodiafiltration-following-fda-clearance 2025-06-04T22:52:40+00:00 hourly 0.9 https://trial.medpath.com/news/b06c7f775a26178f/elucidata-and-sapien-biosciences-form-strategic-partnership-to-transform-india-s-largest-biobank-into-ai-ready-data-platform 2025-06-04T22:51:43+00:00 hourly 0.9 https://trial.medpath.com/news/e79746d1ea22950f/aitia-partners-with-gustave-roussy-to-develop-ai-powered-digital-twins-for-cancer-research 2025-06-04T21:54:01+00:00 hourly 0.9 https://trial.medpath.com/news/e7c6c2b0bd48b593/new-research-reveals-complex-effects-of-ozempic-on-muscle-mass-and-strength 2025-06-04T21:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/5067c76e6902e899/daiichi-sankyo-s-new-ceo-charts-course-for-adc-expansion-beyond-enhertu-success 2025-06-04T20:56:35+00:00 hourly 0.9 https://trial.medpath.com/news/1808992a726152bc/federal-circuit-upholds-moderna-victory-in-covid-19-vaccine-patent-dispute-with-alnylam 2025-06-04T20:56:15+00:00 hourly 0.9 https://trial.medpath.com/news/1f98931e2a5e162e/biotech-funding-plummets-57-to-2-7-billion-as-trump-administration-policies-shake-investor-confidence 2025-06-04T20:54:53+00:00 hourly 0.9 https://trial.medpath.com/news/5b93ee066ea119d5/sanofi-and-gsk-pursue-aggressive-m-a-strategies-while-mrna-technology-faces-economic-headwinds 2025-06-04T20:53:27+00:00 hourly 0.9 https://trial.medpath.com/news/07e19e4c60e1d04a/thio-plus-cemiplimab-demonstrates-promising-activity-in-ici-resistant-advanced-nsclc 2025-06-04T20:52:55+00:00 hourly 0.9 https://trial.medpath.com/news/6a60567219327fff/kfshrc-achieves-breakthrough-in-gene-therapy-for-hemophilia-a-with-one-time-treatment-success 2025-06-04T20:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/61f841efa6810b04/china-courts-signal-shift-in-polymorph-patent-standards-as-beijing-ip-court-lowers-inventiveness-bar 2025-06-04T20:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/9638946399c44f21/fda-awards-sarepta-first-platform-technology-designation-for-gene-therapy-vector 2025-06-04T18:59:55+00:00 hourly 0.9 https://trial.medpath.com/news/c9e82069197fb47f/carbogen-amcis-secures-chf-25-million-co-investment-to-expand-adc-drug-linker-manufacturing-in-switzerland 2025-06-04T17:58:45+00:00 hourly 0.9 https://trial.medpath.com/news/16b91ea97c7c7bb8/cepheid-receives-health-canada-approval-for-next-generation-hiv-viral-load-test 2025-06-04T17:57:07+00:00 hourly 0.9 https://trial.medpath.com/news/94a9f6f6f95e1652/vividion-secures-exclusive-rights-to-first-in-class-wrn-inhibitor-vvd-214-for-msi-high-cancers 2025-06-04T16:56:25+00:00 hourly 0.9 https://trial.medpath.com/news/00674d5c7be8002b/fda-approves-first-drug-free-wearable-device-for-pediatric-nasal-congestion-treatment 2025-06-04T16:55:58+00:00 hourly 0.9 https://trial.medpath.com/news/63d90c2a9fc8d7dd/phase-3-oncology-trials-rarely-demonstrate-meaningful-survival-and-quality-of-life-improvements 2025-06-04T16:54:45+00:00 hourly 0.9 https://trial.medpath.com/news/58fcd6219d529b80/iambic-therapeutics-advances-ai-designed-her2-inhibitor-iam1363-to-dose-optimization-phase 2025-06-04T16:53:16+00:00 hourly 0.9 https://trial.medpath.com/news/c948c34556a361cb/eib-provides-eur30m-to-treefrog-therapeutics-for-parkinson-s-disease-cell-therapy-development 2025-06-04T16:51:53+00:00 hourly 0.9 https://trial.medpath.com/news/6f523020dc6e0d0c/biocytogen-and-nanjing-chia-tai-tianqing-receive-ind-approval-for-second-generation-anti-igf-1r-antibody-ntb003-in-thyroid-eye-disease 2025-06-04T16:51:21+00:00 hourly 0.9 https://trial.medpath.com/news/29a135bb9ecb6bb3/oncovita-receives-fda-orphan-drug-designation-for-oncolytic-measles-virus-therapy-in-pleural-mesothelioma 2025-06-04T16:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/463866ea91782ff8/carbogen-amcis-shanghai-facility-receives-first-drug-manufacturing-license-from-china-s-nmpa 2025-06-04T16:49:30+00:00 hourly 0.9 https://trial.medpath.com/news/79910dc027fd7a7e/repertoire-immune-medicines-appoints-oncology-veteran-as-cmo-advances-tcr-bispecific-toward-phase-1-2-trial 2025-06-04T16:49:24+00:00 hourly 0.9 https://trial.medpath.com/news/82e6b9b0384b304c/lipella-pharmaceuticals-renews-manufacturing-partnership-with-cook-myosite-to-advance-oral-lichen-planus-treatment 2025-06-04T16:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/a299ea96396623b0/usp-opens-advanced-technologies-laboratory-to-strengthen-pharmaceutical-supply-chains-and-manufacturing 2025-06-04T16:49:14+00:00 hourly 0.9 https://trial.medpath.com/news/cdb4b2d337009d09/myriad-genetics-launches-firstgene-multiple-prenatal-screen-with-four-in-one-testing-capability 2025-06-04T16:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/9e355e038ec4b05a/vadadustat-phase-3-data-reveals-geographic-differences-in-ckd-anemia-treatment-outcomes 2025-06-04T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/78d7a3df9fd1f653/ema-issues-strategic-recommendations-to-address-critical-radiopharmaceutical-supply-chain-vulnerabilities-in-europe 2025-06-04T16:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/1baf83dc0633c08e/mhra-issues-first-uk-guidance-for-phage-therapy-development-to-combat-antibiotic-resistant-infections 2025-06-04T16:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/5c96f7cbe38461e4/fresenius-kabi-launches-first-generic-iodixanol-contrast-agent-in-canada-addressing-critical-supply-shortages 2025-06-04T16:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/21c7be256d82a072/annamycin-shows-59-clinical-benefit-rate-in-soft-tissue-sarcoma-lung-metastases-phase-2-trial 2025-06-04T16:46:44+00:00 hourly 0.9 https://trial.medpath.com/news/e75e5994a589f4af/halia-therapeutics-completes-enrollment-in-phase-2a-trial-of-novel-nlrp3-inflammasome-inhibitor-for-myelodysplastic-syndrome 2025-06-04T16:46:42+00:00 hourly 0.9 https://trial.medpath.com/news/434dc50accb88428/biodexa-initiates-phase-2-trial-of-tolimidone-for-type-1-diabetes-treatment 2025-06-04T16:45:49+00:00 hourly 0.9 https://trial.medpath.com/news/58adab16c9b45078/commit-biologics-forms-scientific-advisory-board-to-advance-complement-based-cancer-and-autoimmune-therapies 2025-06-04T14:58:32+00:00 hourly 0.9 https://trial.medpath.com/news/6ace982afd4e50f0/tata-memorial-centre-partners-with-ge-healthcare-to-establish-advanced-cancer-research-innovation-centre 2025-06-04T12:59:55+00:00 hourly 0.9 https://trial.medpath.com/news/4d92d70eea278380/continuity-biosciences-acquires-focal-medical-to-advance-iontophoresis-based-pancreatic-cancer-therapy 2025-06-04T12:58:20+00:00 hourly 0.9 https://trial.medpath.com/news/f3908bc61b52f2d2/buscar-company-acquires-70-stake-in-armorgenix-to-enter-pharmaceutical-market 2025-06-04T12:58:09+00:00 hourly 0.9 https://trial.medpath.com/news/9b69df12707a889e/elpis-biopharmaceuticals-partners-with-singapore-general-hospital-to-advance-next-generation-car-gdt-therapies-for-blood-cancers 2025-06-04T12:57:49+00:00 hourly 0.9 https://trial.medpath.com/news/2858c694fb2994ef/m42-astrazeneca-and-sophia-genetics-launch-uae-liquid-biopsy-initiative-to-transform-cancer-diagnosis 2025-06-04T12:57:29+00:00 hourly 0.9 https://trial.medpath.com/news/1d30a9530fd83399/leon-nanodrugs-appoints-dr-wolfgang-hofmann-as-ceo-to-drive-nanoparticle-manufacturing-technology-commercialization 2025-06-04T12:57:09+00:00 hourly 0.9 https://trial.medpath.com/news/01f087385415615e/wildtype-becomes-first-company-to-launch-cultivated-seafood-in-us-market-following-fda-clearance 2025-06-04T12:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/6cef327ce16e5024/molecular-health-and-axxam-form-strategic-partnership-to-accelerate-ai-driven-drug-target-discovery 2025-06-04T12:56:29+00:00 hourly 0.9 https://trial.medpath.com/news/66d237b803d48b83/saniona-advances-neurological-pipeline-with-strategic-partnerships-and-strong-financial-position 2025-06-04T12:56:20+00:00 hourly 0.9 https://trial.medpath.com/news/4791d1d0aab53246/patent-settlements-accelerate-generic-and-biosimilar-market-entry-generating-423-billion-in-healthcare-savings 2025-06-04T12:55:56+00:00 hourly 0.9 https://trial.medpath.com/news/7f3af3a45652864d/purple-biotech-to-present-novel-captn-3-tri-specific-antibody-platform-at-eacr-2025 2025-06-04T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/82c401c0b9dd02a0/breast-cancer-trials-launches-remote-telehealth-pre-screening-to-expand-access-for-regional-patients 2025-06-04T10:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/719455cfd7fe4a98/traws-pharma-stock-surges-94-following-breakthrough-drug-trial-success 2025-06-04T10:56:33+00:00 hourly 0.9 https://trial.medpath.com/news/217a17619d54bcbe/ai-guided-drug-discovery-identifies-promising-cancer-treatment-combinations-using-existing-non-cancer-medications 2025-06-04T09:56:23+00:00 hourly 0.9 https://trial.medpath.com/news/2111672f7dfd5738/chinese-drug-combination-outperforms-keytruda-in-advanced-lung-cancer-trial 2025-06-04T09:01:38+00:00 hourly 0.9 https://trial.medpath.com/news/900e9b251f1bf8f5/fujirebio-launches-automated-strem2-assay-to-advance-neuroinflammation-research-in-alzheimer-s-disease 2025-06-04T09:00:46+00:00 hourly 0.9 https://trial.medpath.com/news/02da42ed0854cade/bioinvent-advances-bi-1910-anti-tnfr2-antibody-with-population-modeling-data-at-page-2025 2025-06-04T09:00:33+00:00 hourly 0.9 https://trial.medpath.com/news/39e6b01d8008cde0/caltech-s-smart-bandage-technology-demonstrates-early-biomarker-detection-in-first-human-clinical-trial 2025-06-04T09:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/d0f65a7215fad4df/abl-diagnostics-unveils-advanced-hiv-drug-resistance-detection-platform-at-european-meeting 2025-06-04T08:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/e022bf31e3856f66/synact-pharma-secures-sek-30-million-credit-facility-to-advance-rheumatoid-arthritis-drug-development-through-mid-2026 2025-06-04T08:59:52+00:00 hourly 0.9 https://trial.medpath.com/news/f04fea61e21d96dd/psilocybin-clinical-trial-targets-treatment-resistant-ibs-in-groundbreaking-gastroenterology-study 2025-06-04T06:54:58+00:00 hourly 0.9 https://trial.medpath.com/news/d7f8eb35a125975e/akadeum-life-sciences-secures-20m-to-advance-cell-separation-technology-for-gene-and-cell-therapy-manufacturing 2025-06-04T04:57:09+00:00 hourly 0.9 https://trial.medpath.com/news/11ff63edd03370dd/transpire-bio-licenses-pde4-inhibitor-itg-1052-for-idiopathic-pulmonary-fibrosis-treatment 2025-06-04T01:52:40+00:00 hourly 0.9 https://trial.medpath.com/news/e85066a3577eb88a/phase-3-trial-shows-promise-for-adjuvant-braf-mek-inhibitor-combination-in-high-risk-melanoma 2025-06-04T00:58:58+00:00 hourly 0.9 https://trial.medpath.com/news/c7c3fe218e89b29c/car-t-immunotherapy-shows-unprecedented-five-year-survival-in-advanced-multiple-myeloma-patients 2025-06-04T00:58:47+00:00 hourly 0.9 https://trial.medpath.com/news/4675f4461d6024dd/computer-modeling-identifies-two-broad-spectrum-antiviral-compounds-against-rna-viruses 2025-06-04T00:57:59+00:00 hourly 0.9 https://trial.medpath.com/news/deac2a4ee1f9b5b9/daewoong-pharmaceutical-advances-phase-2-trial-of-novel-ipf-drug-bersiporocin-with-diverse-patient-population 2025-06-04T00:57:51+00:00 hourly 0.9 https://trial.medpath.com/news/e3eb7f12799fea8b/moderna-agrees-to-placebo-controlled-trial-for-new-covid-19-vaccine-following-fda-approval 2025-06-04T00:57:44+00:00 hourly 0.9 https://trial.medpath.com/news/daf6b369f3abc32a/circulating-tumor-dna-emerges-as-powerful-prognostic-biomarker-in-locally-advanced-cervical-cancer 2025-06-04T00:56:17+00:00 hourly 0.9 https://trial.medpath.com/news/51050ea02847fda1/asco-2025-showcases-advances-in-myelofibrosis-treatment-with-novel-jak-inhibitors-and-personalized-approaches 2025-06-04T00:56:12+00:00 hourly 0.9 https://trial.medpath.com/news/0270a1ee5cd0cba0/essential-thrombocythemia-market-set-for-significant-growth-as-novel-therapies-enter-pipeline 2025-06-04T00:56:10+00:00 hourly 0.9 https://trial.medpath.com/news/0c8a62b6c4b60df7/ascletis-first-in-class-acne-drug-denifanstat-meets-all-phase-iii-endpoints-outperforms-fda-approved-treatments 2025-06-04T00:52:56+00:00 hourly 0.9 https://trial.medpath.com/news/9529513535ec4657/redwire-secures-contract-with-aspera-biomedicines-for-space-based-cancer-research-using-adar1-inhibitor-rebecsinib 2025-06-04T00:52:24+00:00 hourly 0.9 https://trial.medpath.com/news/77e6a6e7a2d9a62b/aravax-strengthens-leadership-team-with-regulatory-expert-louise-peacock-ahead-of-phase-3-peanut-allergy-trial 2025-06-03T22:55:51+00:00 hourly 0.9 https://trial.medpath.com/news/8ff1a2cb4ed5e457/camurus-and-eli-lilly-forge-870-million-partnership-for-long-acting-diabetes-and-obesity-therapies 2025-06-03T21:54:11+00:00 hourly 0.9 https://trial.medpath.com/news/5efe95c8e8df8c38/congruence-therapeutics-advances-cgx-926-for-rare-genetic-obesity-as-company-presents-novel-mc4r-corrector-data 2025-06-03T21:51:32+00:00 hourly 0.9 https://trial.medpath.com/news/80f31d1457fe2d6f/quidelortho-pivots-molecular-diagnostics-strategy-with-100m-lex-diagnostics-acquisition 2025-06-03T21:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/527cf946dede2ac4/us-court-allows-lupin-and-zydus-to-expand-patent-defense-arguments-in-myrbetriq-generic-drug-case 2025-06-03T20:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/37d3943f6f9e07ea/dante-trial-shows-promise-for-shorter-immunotherapy-duration-in-advanced-melanoma 2025-06-03T20:59:44+00:00 hourly 0.9 https://trial.medpath.com/news/a8a00490c0628e7f/huntington-s-disease-pipeline-shows-robust-growth-with-20-companies-developing-novel-therapies 2025-06-03T20:57:34+00:00 hourly 0.9 https://trial.medpath.com/news/27f0a5a2ec4c189f/aspaveli-demonstrates-sustained-68-proteinuria-reduction-in-phase-3-valiant-trial-for-rare-kidney-diseases 2025-06-03T20:57:21+00:00 hourly 0.9 https://trial.medpath.com/news/40e8b11630954e14/fda-approves-darolutamide-for-metastatic-castration-sensitive-prostate-cancer-based-on-aranote-trial-results 2025-06-03T20:53:15+00:00 hourly 0.9 https://trial.medpath.com/news/5c14a69ba8f23a56/leyden-labs-secures-eur20-million-eib-funding-to-advance-pan-influenza-nasal-spray-development 2025-06-03T19:51:41+00:00 hourly 0.9 https://trial.medpath.com/news/3efff0520df2a2e1/leo-pharma-launches-phase-2a-trial-of-delgocitinib-cream-for-rare-skin-disease-palmoplantar-pustulosis 2025-06-03T18:53:49+00:00 hourly 0.9 https://trial.medpath.com/news/8ab1ea1e5d41985f/brain-training-game-shows-promise-for-drug-free-nerve-pain-treatment-in-first-clinical-trial 2025-06-03T18:51:52+00:00 hourly 0.9 https://trial.medpath.com/news/e562ad82f6dc94ad/affinia-therapeutics-partners-with-dcm-foundation-to-advance-bag3-dilated-cardiomyopathy-awareness-and-genetic-testing 2025-06-03T18:51:15+00:00 hourly 0.9 https://trial.medpath.com/news/4f31832c3da137ba/jasper-therapeutics-to-present-briquilimab-clinical-data-at-eaaci-congress-2025 2025-06-03T17:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/9d77b1bf18945104/zydus-lifesciences-secures-exclusive-rights-to-agenus-bot-bal-cancer-immunotherapy-for-india-and-sri-lanka 2025-06-03T17:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/8ccc749c87963938/antheia-secures-56m-series-c-to-scale-synthetic-biology-platform-for-critical-drug-manufacturing 2025-06-03T17:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/efe759ab6b9c72ff/sun-pharma-discontinues-psoriasis-and-eczema-drug-scd-044-after-phase-2-trial-failures 2025-06-03T17:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/869323699e1b8b2b/russia-s-personalized-mrna-cancer-vaccine-set-for-clinical-launch-by-october-2025 2025-06-03T17:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/528b5056b9a27f8c/allergan-botox-patent-infringement-trial-against-revance-set-for-july-in-delaware 2025-06-03T17:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/7eec395973467e2b/patent-trial-and-appeal-board-institutes-review-against-halozyme-in-merck-patent-dispute 2025-06-03T17:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/10f1b4565e2e2b12/trexbio-initiates-first-in-human-trial-of-trb-061-novel-tnfr2-agonist-for-atopic-dermatitis 2025-06-03T17:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/7807ffe87ced6ab1/ocu410-gene-therapy-shows-promise-for-geographic-atrophy-with-single-dose-treatment-approach 2025-06-03T17:00:52+00:00 hourly 0.9 https://trial.medpath.com/news/7b72fb75ae1802d1/mentaily-secures-3m-seed-funding-for-ai-powered-mental-health-diagnostic-platform-liv 2025-06-03T17:00:46+00:00 hourly 0.9 https://trial.medpath.com/news/951e5fa98e757414/vera-therapeutics-secures-500-million-credit-facility-to-support-atacicept-commercial-launch 2025-06-03T17:00:10+00:00 hourly 0.9 https://trial.medpath.com/news/0d26ac3fd0df87eb/bioage-expands-apj-agonist-pipeline-with-novel-oral-and-injectable-candidates-for-enhanced-obesity-treatment 2025-06-03T16:59:03+00:00 hourly 0.9 https://trial.medpath.com/news/c106c7abf6ad49af/reshape-lifesciences-achieves-early-eu-mdr-certification-for-obesity-treatment-devices 2025-06-03T16:59:01+00:00 hourly 0.9 https://trial.medpath.com/news/78129a0dd639c32b/beam-therapeutics-receives-fda-orphan-drug-designation-for-beam-101-sickle-cell-disease-therapy 2025-06-03T16:58:59+00:00 hourly 0.9 https://trial.medpath.com/news/2604540b1fd83816/abbvie-s-temab-a-adc-shows-63-response-rate-in-egfr-mutated-nsclc-phase-i-trial 2025-06-03T16:56:29+00:00 hourly 0.9 https://trial.medpath.com/news/486409e31226cd4a/amplitude-trial-shows-niraparib-combination-reduces-cancer-progression-risk-by-37-in-hrr-mutant-metastatic-prostate-cancer 2025-06-03T16:54:14+00:00 hourly 0.9 https://trial.medpath.com/news/edcd21f31efd6e67/sanofi-s-sarclisa-shows-non-inferior-efficacy-with-novel-on-body-injector-in-phase-3-multiple-myeloma-trial 2025-06-03T15:52:41+00:00 hourly 0.9 https://trial.medpath.com/news/b82527bce51ae9fa/matter-neuroscience-partners-with-stanford-medicine-to-test-novel-fmri-guided-depression-therapy 2025-06-03T13:51:09+00:00 hourly 0.9 https://trial.medpath.com/news/c383e878b1a3df7c/catalyst-pharmaceuticals-appoints-dr-william-andrews-as-chief-medical-officer-to-lead-rare-disease-strategy 2025-06-03T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/012f048f05498aa8/flot-chemotherapy-demonstrates-superior-survival-and-distant-recurrence-control-over-cross-in-esophageal-adenocarcinoma 2025-06-03T13:48:11+00:00 hourly 0.9 https://trial.medpath.com/news/bb1a59b290df23af/researchers-develop-trans-amplifying-mrna-vaccine-platform-with-40-fold-dose-reduction-and-broad-viral-protection 2025-06-03T12:57:12+00:00 hourly 0.9 https://trial.medpath.com/news/3e22af3e0fcb9b3a/minerva-biotechnologies-advances-muc1-targeted-car-t-therapy-with-1xx-mutations-for-solid-tumors 2025-06-03T12:56:43+00:00 hourly 0.9 https://trial.medpath.com/news/f4fabdc45c9b29b8/kamari-pharma-secures-23-million-series-a-to-advance-first-in-class-trpv3-inhibitor-for-rare-genetic-skin-diseases 2025-06-03T12:55:49+00:00 hourly 0.9 https://trial.medpath.com/news/6fa641e195713370/rigosertib-achieves-80-response-rate-in-first-clinical-trial-for-rare-rdeb-associated-skin-cancer 2025-06-03T12:55:11+00:00 hourly 0.9 https://trial.medpath.com/news/53ba214a7efb0adb/japanese-researchers-launch-final-phase-trial-of-bromocriptine-for-familial-alzheimer-s-disease 2025-06-03T12:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/a693d1eb512bc09e/markherz-partners-with-tum-hospital-to-advance-aav-gene-therapy-for-cardiovascular-disease 2025-06-03T12:53:55+00:00 hourly 0.9 https://trial.medpath.com/news/1eb9277e2111ce9e/spago-nanomedical-s-radioligand-therapy-177lu-sn201-advances-in-phase-i-iia-trial-following-positive-safety-review 2025-06-03T12:53:16+00:00 hourly 0.9 https://trial.medpath.com/news/d26c019defc932c4/biocon-receives-cdsco-approval-for-liraglutide-diabetes-drug-in-india 2025-06-03T09:01:03+00:00 hourly 0.9 https://trial.medpath.com/news/b2d93be2e79ba848/jade-biosciences-to-present-preclinical-data-on-jade101-anti-april-antibody-for-iga-nephropathy-at-european-renal-congress 2025-06-03T08:55:21+00:00 hourly 0.9 https://trial.medpath.com/news/cf1652658855d8b0/nutriband-advances-aversa-fentanyl-abuse-deterrent-patch-development-with-kindeva-partnership 2025-06-03T07:56:07+00:00 hourly 0.9 https://trial.medpath.com/news/768f9f33930edb3a/spyglass-pharma-secures-75-million-series-d-to-advance-long-term-glaucoma-drug-delivery-platform-through-phase-iii-trials 2025-06-03T06:54:01+00:00 hourly 0.9 https://trial.medpath.com/news/b5a5ec6dc0a69462/sony-screen-and-vitrovo-launch-high-density-mea-system-trial-for-drug-discovery-and-neurological-disease-research 2025-06-03T05:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/47b9393e2308c669/terbium-161-radioimmunotherapy-shows-superior-efficacy-against-lymphoma-in-preclinical-studies 2025-06-03T04:55:11+00:00 hourly 0.9 https://trial.medpath.com/news/ca154ad90b65d51e/amivantamab-shows-promise-in-colorectal-cancer-as-phase-3-trials-launch-following-encouraging-phase-1b-2-results 2025-06-03T04:51:45+00:00 hourly 0.9 https://trial.medpath.com/news/9e4b9900e046f86a/comprehensive-biomarker-and-prognostic-framework-emerges-for-attr-cm-disease-monitoring 2025-06-03T02:52:03+00:00 hourly 0.9 https://trial.medpath.com/news/395af417d8208c4f/fda-grants-first-ever-authorization-for-ai-platform-to-predict-breast-cancer-risk-from-mammograms 2025-06-03T01:51:47+00:00 hourly 0.9 https://trial.medpath.com/news/fa8cfb9b58da27cf/qiagen-partners-with-foresight-diagnostics-and-tracer-biotechnologies-to-expand-minimal-residual-disease-testing-portfolio 2025-06-03T01:50:45+00:00 hourly 0.9 https://trial.medpath.com/news/357b916d2e67169d/trastuzumab-deruxtecan-combination-reduces-disease-progression-risk-by-44-in-her2-positive-metastatic-breast-cancer 2025-06-03T00:58:31+00:00 hourly 0.9 https://trial.medpath.com/news/9575e94f0ab97e3c/real-world-study-shows-belantamab-mafodotin-maintains-efficacy-in-high-risk-multiple-myeloma-patients-despite-treatment-withdrawal 2025-06-03T00:57:19+00:00 hourly 0.9 https://trial.medpath.com/news/6ca1c245b56604d2/extended-low-dose-apixaban-reduces-vte-recurrence-by-87-in-high-risk-patients 2025-06-03T00:55:23+00:00 hourly 0.9 https://trial.medpath.com/news/0b61df4310c536fd/immuneoncia-s-cd47-antibody-imc-002-shows-30-response-rate-in-advanced-hepatocellular-carcinoma-trial 2025-06-03T00:55:21+00:00 hourly 0.9 https://trial.medpath.com/news/bb2db4e58a99ce5d/merck-explores-3-billion-acquisition-of-swiss-biotech-moonlake-immunotherapeutics 2025-06-03T00:53:03+00:00 hourly 0.9 https://trial.medpath.com/news/ce5ebc1b4035b031/atai-life-sciences-and-beckley-psytech-announce-390-million-merger-to-create-psychedelic-mental-health-leader 2025-06-03T00:52:34+00:00 hourly 0.9 https://trial.medpath.com/news/181305d61e6025c6/novel-antibody-drug-conjugate-achieves-85-response-rate-in-rare-blood-cancer-trial 2025-06-03T00:50:31+00:00 hourly 0.9 https://trial.medpath.com/news/4c4f0baf67071ced/allogeneic-cell-therapies-emerge-as-next-generation-cancer-treatment-to-address-manufacturing-and-cost-challenges 2025-06-03T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/4c83455157c909a4/jenscare-reports-positive-clinical-outcomes-for-tricuspid-and-mitral-valve-interventions-at-europcr-2025 2025-06-03T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/2c11787ea6c94b02/bayer-submits-low-dose-mri-contrast-agent-gadoquatrane-for-global-regulatory-approval 2025-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/42148e30f6162e13/freenome-s-blood-based-colorectal-cancer-test-achieves-landmark-results-in-largest-prospective-study 2025-06-02T23:52:12+00:00 hourly 0.9 https://trial.medpath.com/news/78b1510833fe19bd/biocartis-achieves-first-ivdr-class-c-companion-diagnostic-certification-for-egfr-mutation-test-in-europe 2025-06-02T22:54:10+00:00 hourly 0.9 https://trial.medpath.com/news/43b57c15de3a44f9/vantive-announces-1-billion-investment-in-digital-kidney-care-technologies-over-five-years 2025-06-02T22:53:24+00:00 hourly 0.9 https://trial.medpath.com/news/3bea1923a972152e/rly-2608-shows-promise-in-pik3ca-mutant-breast-cancer-with-improved-tolerability-profile 2025-06-02T21:53:51+00:00 hourly 0.9 https://trial.medpath.com/news/aa69d7cefc04cefc/curogen-appoints-industry-veteran-arvind-sood-as-global-coo-to-lead-us-expansion-of-nanotechnology-based-autoimmune-therapies 2025-06-02T21:50:44+00:00 hourly 0.9 https://trial.medpath.com/news/673c5056580d2dc4/protara-therapeutics-appoints-william-conkling-as-chief-commercial-officer-to-lead-commercialization-strategy 2025-06-02T21:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/4f8ce476d7226910/five-year-data-show-lasting-survival-benefits-from-single-dose-til-therapy-in-advanced-melanoma 2025-06-02T21:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/e8d890d5022e88ca/researchers-develop-high-throughput-lectin-based-screening-method-to-optimize-sialic-acid-glycosylation-in-drug-development 2025-06-02T20:58:33+00:00 hourly 0.9 https://trial.medpath.com/news/9479f9c2515c5e5a/frontage-laboratories-expands-manufacturing-capabilities-with-new-46300-sq-ft-crdmo-facility-in-pennsylvania 2025-06-02T20:56:43+00:00 hourly 0.9 https://trial.medpath.com/news/6f5674670d6af619/rebecsinib-becomes-first-space-tested-cancer-drug-to-enter-clinical-trials 2025-06-02T20:56:24+00:00 hourly 0.9 https://trial.medpath.com/news/98f4c698ddb11189/eisai-s-lenvima-combination-therapy-receives-chinese-approval-for-unresectable-hepatocellular-carcinoma 2025-06-02T19:53:43+00:00 hourly 0.9 https://trial.medpath.com/news/e5a01eeaa0c42d80/berkshire-biomedical-secures-2-9m-nih-grant-for-biometric-methadone-dispensing-system-clinical-study 2025-06-02T17:54:07+00:00 hourly 0.9 https://trial.medpath.com/news/ffbb1cb69dd425f1/enterome-reports-positive-phase-2-data-for-eo2463-in-indolent-non-hodgkin-lymphoma 2025-06-02T17:53:44+00:00 hourly 0.9 https://trial.medpath.com/news/06b100ac56a85ec6/culturally-tailored-intervention-shows-promise-for-latina-breast-cancer-survivors-in-randomized-trial 2025-06-02T17:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/679b9de5fe909d0a/henlius-presents-comprehensive-serplulimab-data-at-asco-2025-demonstrating-broad-efficacy-across-multiple-cancer-types 2025-06-02T17:52:04+00:00 hourly 0.9 https://trial.medpath.com/news/b6744e9173b6ad8b/sbrt-addition-to-nivolumab-ipilimumab-fails-to-improve-outcomes-in-metastatic-castration-resistant-prostate-cancer 2025-06-02T17:51:22+00:00 hourly 0.9 https://trial.medpath.com/news/9cf63bd29ab969ba/arrowhead-pharmaceuticals-launches-first-in-human-trial-of-aro-alk7-for-obesity-treatment 2025-06-02T17:50:41+00:00 hourly 0.9 https://trial.medpath.com/news/de40ab3d4a2bd92c/regeneron-s-trevogrumab-shows-promise-in-preserving-muscle-mass-when-combined-with-wegovy-in-weight-loss-study 2025-06-02T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/1558b8ed5dd56dee/oncusp-s-cdh6-directed-adc-cusp06-shows-36-response-rate-in-platinum-resistant-ovarian-cancer 2025-06-02T17:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/f10e644ab0a83482/kivu-bioscience-partners-with-sterling-pharma-for-phase-1-manufacturing-of-next-generation-adc-kivu-107 2025-06-02T17:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/9765bf69e6e9aeb2/newcastle-university-researchers-identify-novel-cd30-targeting-combination-therapy-to-overcome-immune-checkpoint-blockade-resistance-in-melanoma 2025-06-02T17:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/cd8418bedfbe796d/mink-therapeutics-secures-niaid-grant-to-develop-inkt-cell-therapy-for-graft-versus-host-disease-prevention 2025-06-02T17:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/fa934b3b9498c92f/biocon-receives-indian-regulatory-approval-for-generic-liraglutide-expanding-glp-1-diabetes-treatment-access 2025-06-02T17:02:12+00:00 hourly 0.9 https://trial.medpath.com/news/82b8cec22993017c/regeneron-licenses-chinese-glp-1-gip-dual-agonist-in-2-billion-obesity-deal-with-hansoh-pharma 2025-06-02T17:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/264604dab7254209/intranasal-monoclonal-antibody-therapy-shows-promise-against-mugwort-pollen-allergy-in-preclinical-study 2025-06-02T17:01:51+00:00 hourly 0.9 https://trial.medpath.com/news/7b45c18ac8e99b83/china-patent-board-upholds-rnai-therapeutic-patents-despite-broad-claim-challenges 2025-06-02T17:01:15+00:00 hourly 0.9 https://trial.medpath.com/news/8ffcef3f8c6bb70d/coya-therapeutics-secures-key-patent-for-il-2-liquid-formulation-advances-als-combination-therapy 2025-06-02T17:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/1eb317d6f3ad1618/neoadjuvant-nivolumab-plus-chemotherapy-demonstrates-10-survival-advantage-in-resectable-nsclc-at-5-year-follow-up 2025-06-02T17:01:04+00:00 hourly 0.9 https://trial.medpath.com/news/007809e99b208660/dll3-targeted-car-t-therapy-lb2102-shows-promise-in-relapsed-refractory-small-cell-lung-cancer 2025-06-02T17:01:03+00:00 hourly 0.9 https://trial.medpath.com/news/78816cc7e6098251/sutro-biopharma-appoints-greg-chow-as-cfo-to-advance-adc-pipeline 2025-06-02T16:59:16+00:00 hourly 0.9 https://trial.medpath.com/news/c9e64fa4d85279ec/instil-bio-appoints-veteran-oncologist-jamie-freedman-as-chief-medical-officer-to-advance-pd-l1xvegf-bispecific 2025-06-02T16:59:14+00:00 hourly 0.9 https://trial.medpath.com/news/d78a6a8fa93a502e/lilly-s-next-generation-adc-shows-55-response-rate-in-platinum-resistant-ovarian-cancer 2025-06-02T16:59:09+00:00 hourly 0.9 https://trial.medpath.com/news/fd52a705316e5677/oxford-cancer-biomarkers-partners-with-mira-precision-health-to-advance-toxnav-r-test-for-5fu-capecitabine-toxicity-prediction-in-us-market 2025-06-02T16:59:07+00:00 hourly 0.9 https://trial.medpath.com/news/da1e9c078d919a86/swog-s2302-pragmatica-lung-trial-fails-to-show-survival-benefit-but-sets-new-standard-for-streamlined-cancer-research 2025-06-02T16:56:05+00:00 hourly 0.9 https://trial.medpath.com/news/7b0cc2d3e040054e/dyadic-international-appoints-joe-hazelton-as-president-to-lead-strategic-pivot-to-ancillary-protein-markets 2025-06-02T16:55:56+00:00 hourly 0.9 https://trial.medpath.com/news/b3c28c10b62ca149/viz-ai-partners-with-novartis-to-develop-ai-powered-cancer-care-solutions-for-prostate-and-breast-cancer 2025-06-02T16:55:54+00:00 hourly 0.9 https://trial.medpath.com/news/da60fc5d15c9ba88/outlook-therapeutics-launches-first-approved-ophthalmic-bevacizumab-in-europe-for-wet-amd-treatment 2025-06-02T16:55:50+00:00 hourly 0.9 https://trial.medpath.com/news/556ebd4b6c6840f7/vera-therapeutics-atacicept-achieves-46-proteinuria-reduction-in-phase-3-iga-nephropathy-trial 2025-06-02T16:55:41+00:00 hourly 0.9 https://trial.medpath.com/news/574e818a11ac02e6/danhong-injection-shows-promise-in-reducing-inflammation-and-improving-vascular-function-in-unstable-angina-patients 2025-06-02T16:55:37+00:00 hourly 0.9 https://trial.medpath.com/news/61674c998387f505/evosep-launches-high-throughput-proteomics-platform-eno-and-expands-sciex-partnership-at-asms-2025 2025-06-02T16:54:44+00:00 hourly 0.9 https://trial.medpath.com/news/5594bd5768ea36a4/stemcell-technologies-acquires-cellular-highways-to-advance-cell-therapy-manufacturing-with-revolutionary-vacs-technology 2025-06-02T16:53:33+00:00 hourly 0.9 https://trial.medpath.com/news/d1b7b3164688c6ff/4d-path-s-digital-biomarker-identifies-treatment-responders-in-previously-resistant-breast-cancer-patients 2025-06-02T16:53:15+00:00 hourly 0.9 https://trial.medpath.com/news/18a765bd0c750019/pfizer-and-biontech-submit-ema-application-for-updated-covid-19-vaccine-targeting-lp-8-1-strain-for-2025-2026-season 2025-06-02T16:53:07+00:00 hourly 0.9 https://trial.medpath.com/news/35cde48855a2cd81/ibudilast-fails-to-show-efficacy-for-alcohol-use-disorder-in-phase-2-trial-but-shows-promise-for-women 2025-06-02T16:52:39+00:00 hourly 0.9 https://trial.medpath.com/news/94799a8121e9b76b/vistagen-advances-fasedienol-phase-3-program-for-social-anxiety-disorder-with-q4-2025-data-readout 2025-06-02T16:52:05+00:00 hourly 0.9 https://trial.medpath.com/news/432b8ae1c13bef87/ferroptosis-emerges-as-novel-therapeutic-target-in-cancer-treatment-and-immunotherapy 2025-06-02T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a242cfae417579c1/breakthrough-immunotherapy-response-in-rare-lung-adenosquamous-carcinoma-with-multiple-driver-mutations 2025-06-02T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/62742a130939e904/immunabs-receives-fda-clearance-for-phase-2-trial-of-im-101-complement-inhibitor-in-myasthenia-gravis 2025-06-02T13:52:34+00:00 hourly 0.9 https://trial.medpath.com/news/c12e34db803d7763/alneo-trial-demonstrates-promising-perioperative-alectinib-activity-in-stage-iii-alk-positive-nsclc 2025-06-02T13:52:08+00:00 hourly 0.9 https://trial.medpath.com/news/aebd30e0f635ca8c/beone-medicines-reports-promising-early-data-for-two-novel-breast-cancer-therapies-at-asco-2025 2025-06-02T12:51:24+00:00 hourly 0.9 https://trial.medpath.com/news/8f2253428bef220d/kalvista-s-sebetralstat-halts-hereditary-angioedema-attacks-in-median-19-8-minutes-across-clinical-trials 2025-06-02T12:50:30+00:00 hourly 0.9 https://trial.medpath.com/news/fc2d31054400ab36/bristol-myers-squibb-partners-with-biontech-in-11-1-billion-deal-for-dual-target-cancer-immunotherapy 2025-06-02T12:49:46+00:00 hourly 0.9 https://trial.medpath.com/news/db278979e3cb41f1/vera-therapeutics-atacicept-achieves-46-protein-reduction-in-phase-3-iga-nephropathy-trial 2025-06-02T12:49:37+00:00 hourly 0.9 https://trial.medpath.com/news/99db20386788fe02/viatris-reports-positive-phase-3-results-for-mr-142-in-treating-night-vision-disturbances-after-refractive-surgery 2025-06-02T12:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/517ca5684e27c56e/defence-therapeutics-establishes-first-u-s-laboratory-in-boston-cambridge-to-advance-adc-technology 2025-06-02T12:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/f29815f53f9e271c/nice-recommends-eli-lilly-s-mirikizumab-for-crohn-s-disease-treatment-following-positive-phase-3-trial-results 2025-06-02T12:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/0b5eb2cffef203d3/relay-therapeutics-reports-sustained-efficacy-for-rly-2608-in-pi3ka-mutated-breast-cancer-at-asco-2025 2025-06-02T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/0260938f8abd6079/terumo-neuro-launches-sofia-flow-88-neurovascular-aspiration-catheter-in-emea-markets 2025-06-02T10:54:50+00:00 hourly 0.9 https://trial.medpath.com/news/fa350886ad9d60f7/mhra-approves-serplulimab-as-first-anti-pd-1-therapy-for-small-cell-lung-cancer-in-uk 2025-06-02T09:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/f2f167d818efe0e9/asp-isotopes-and-isotopia-forge-strategic-partnership-to-accelerate-terbium-161-cancer-therapy-production 2025-06-02T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d7e48292a700e41b/mixed-results-for-adjuvant-immunotherapy-in-high-risk-cutaneous-squamous-cell-carcinoma 2025-06-02T08:56:01+00:00 hourly 0.9 https://trial.medpath.com/news/330014e83a06b206/deepeye-medical-receives-ce-mark-for-ai-powered-therapy-planning-assistant-for-amd-treatment 2025-06-02T08:53:40+00:00 hourly 0.9 https://trial.medpath.com/news/e6cf0aa1431a032c/sandoz-launches-first-interchangeable-denosumab-biosimilars-in-us-expanding-access-for-osteoporosis-and-cancer-patients 2025-06-02T08:52:45+00:00 hourly 0.9 https://trial.medpath.com/news/60e88f6d76d07408/sanofi-acquires-blueprint-medicines-for-9-1-billion-to-strengthen-rare-disease-and-immunology-portfolio 2025-06-02T08:52:37+00:00 hourly 0.9 https://trial.medpath.com/news/7c2f5aa9215e59ca/fda-denies-approval-for-elamipretide-despite-dramatic-heart-function-improvements-in-barth-syndrome-patients 2025-06-02T08:52:29+00:00 hourly 0.9 https://trial.medpath.com/news/fd44dc1e935c5313/innocare-presents-promising-clinical-data-for-multiple-oncology-pipeline-candidates-at-major-medical-conferences 2025-06-02T05:52:28+00:00 hourly 0.9 https://trial.medpath.com/news/5ac7fe0ec7942314/fda-tightens-nitrosamine-testing-requirements-with-new-guidelines-taking-effect-this-august 2025-06-02T04:54:23+00:00 hourly 0.9 https://trial.medpath.com/news/47d7539a26f24022/j-ints-bio-s-fourth-generation-egfr-tki-jin-a02-shows-promising-anti-tumor-activity-in-resistant-nsclc-patients 2025-06-02T04:53:33+00:00 hourly 0.9 https://trial.medpath.com/news/07c92bc4db196017/imugene-activates-first-australian-site-for-phase-ii-colorectal-cancer-vaccine-trial 2025-06-02T04:52:49+00:00 hourly 0.9 https://trial.medpath.com/news/d920142291a8ad35/researchers-unveil-new-strategies-to-harness-tumor-microenvironment-for-enhanced-cancer-immunotherapy 2025-06-02T03:56:20+00:00 hourly 0.9 https://trial.medpath.com/news/9fff69cebb220453/novartis-secures-fda-approval-for-leqvio-first-twice-yearly-cholesterol-drug 2025-06-02T03:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/0cca0dc72d686b99/mammaprint-70-gene-assay-shows-strong-predictive-value-for-chemotherapy-benefit-in-hr-her2-breast-cancer 2025-06-02T02:51:24+00:00 hourly 0.9 https://trial.medpath.com/news/2454998cfbe47d18/era-2025-to-feature-pivotal-nephrology-trials-including-confidence-achieve-and-visionary-studies 2025-06-02T02:51:23+00:00 hourly 0.9 https://trial.medpath.com/news/6c407adb7478f05a/novoxel-and-gpophtho-partner-to-expand-access-to-fda-cleared-tixel-device-for-dry-eye-treatment-across-us 2025-06-02T01:50:58+00:00 hourly 0.9 https://trial.medpath.com/news/4e1ad349a3ff97a5/nxera-pharma-achieves-key-development-milestone-in-eli-lilly-collaboration-for-diabetes-and-metabolic-disease-treatments 2025-06-02T00:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/8123c0ce0bf9667d/mhra-grants-conditional-approval-for-car-t-therapy-aucatzyl-to-treat-relapsed-b-cell-all 2025-06-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/678c2ce095fc915d/mirvie-s-rna-blood-test-predicts-preeclampsia-risk-months-before-symptoms-in-major-study 2025-06-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/470311cfcdcd6214/real-world-data-confirms-low-severity-safety-profile-for-lisocabtagene-maraleucel-across-blood-cancer-settings 2025-06-01T20:51:31+00:00 hourly 0.9 https://trial.medpath.com/news/1f4626449b97141e/sintilimab-chidamide-combination-shows-promising-results-in-early-stage-natural-killer-t-cell-lymphoma 2025-06-01T18:50:24+00:00 hourly 0.9 https://trial.medpath.com/news/79e3ac3fc406e916/anti-inflammatory-diet-reduces-death-risk-by-87-in-stage-iii-colon-cancer-patients 2025-06-01T17:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/b03dbf3497a799d6/real-world-data-shows-yescarta-car-t-therapy-safe-and-effective-in-outpatient-setting 2025-06-01T17:51:33+00:00 hourly 0.9 https://trial.medpath.com/news/767d05d1694dfd79/gilead-s-dual-target-car-t-therapy-achieves-62-response-rate-in-recurrent-glioblastoma 2025-06-01T16:54:28+00:00 hourly 0.9 https://trial.medpath.com/news/fa1bff2408d69fa7/dual-target-car-t-cell-therapy-achieves-tumor-shrinkage-in-62-of-recurrent-glioblastoma-patients 2025-06-01T16:53:30+00:00 hourly 0.9 https://trial.medpath.com/news/9a3809051f6e5f10/world-first-clinical-trial-demonstrates-exercise-significantly-improves-colon-cancer-survival 2025-06-01T16:53:21+00:00 hourly 0.9 https://trial.medpath.com/news/c5f8e32dcf2a87cc/casdatifan-plus-cabozantinib-combination-shows-46-response-rate-in-kidney-cancer-trial 2025-06-01T16:52:28+00:00 hourly 0.9 https://trial.medpath.com/news/6751c82e1dc8a84a/johnson-johnson-s-pasritamig-shows-promising-anti-tumor-activity-in-first-in-human-prostate-cancer-trial 2025-06-01T16:52:26+00:00 hourly 0.9 https://trial.medpath.com/news/e9e819984b0fc475/structured-exercise-program-reduces-colon-cancer-recurrence-by-28-in-landmark-international-trial 2025-06-01T16:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/5a26263506a83c30/regorafenib-shows-promise-as-first-line-treatment-for-multi-metastatic-ewing-sarcoma-in-phase-ib-trial 2025-06-01T16:50:14+00:00 hourly 0.9 https://trial.medpath.com/news/fe9434cbc8fd003d/atezolizumab-plus-chemotherapy-reduces-recurrence-risk-by-50-in-stage-iii-dmmr-colon-cancer 2025-06-01T16:49:30+00:00 hourly 0.9 https://trial.medpath.com/news/5e652085a0c2c6c8/replimune-s-rp1-combination-shows-enhanced-response-rates-with-deep-tumor-injections-in-anti-pd-1-failed-melanoma 2025-06-01T16:49:28+00:00 hourly 0.9 https://trial.medpath.com/news/578d800eb767b508/narirutin-accelerates-diabetic-wound-healing-through-ampk-mfn2-mediated-metabolic-reprogramming 2025-06-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/14e4d2553da19e76/cdsco-requests-additional-clinical-data-from-fresenius-for-calcium-chloride-infusion-approval-in-india 2025-06-01T12:43:45+00:00 hourly 0.9 https://trial.medpath.com/news/d4b8fa272dd241ea/dea-blocks-cannabis-research-for-seven-years-despite-fda-approved-clinical-trials-for-huntington-s-disease-and-multiple-sclerosis 2025-06-01T12:43:39+00:00 hourly 0.9 https://trial.medpath.com/news/cd0805673c25bc7f/inxmed-reports-breakthrough-results-for-ifebemtinib-garsorasib-combination-in-kras-g12c-mutant-cancers-at-asco-2025 2025-06-01T08:57:43+00:00 hourly 0.9 https://trial.medpath.com/news/29704427b8575f09/gut-microbiome-emerges-as-key-factor-in-cancer-immunotherapy-response-and-resistance 2025-06-01T03:53:03+00:00 hourly 0.9 https://trial.medpath.com/news/a5dd8e3836fc8b83/lbl-024-bispecific-antibody-shows-75-response-rate-in-advanced-neuroendocrine-carcinoma-trial 2025-06-01T00:46:02+00:00 hourly 0.9 https://trial.medpath.com/news/01215ee0f0391148/neocoast-2-trial-shows-promise-for-novel-pre-surgical-combinations-in-resectable-nsclc 2025-06-01T00:45:10+00:00 hourly 0.9 https://trial.medpath.com/news/808fd27cfb4c09b4/avistone-s-dual-target-therapy-shows-50-response-rate-in-egfr-resistant-lung-cancer-at-asco-2025 2025-06-01T00:44:32+00:00 hourly 0.9 https://trial.medpath.com/news/3c9742a469641b36/astrazeneca-initiates-phase-ii-trial-of-azd7798-for-crohn-s-disease-mucosal-repair 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2a2be01fa9b0c6ff/china-approves-first-domestically-developed-9-valent-hpv-vaccine-becomes-second-country-with-independent-high-valency-hpv-production 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fb4b623b0601b37e/md-anderson-partners-with-healthex-to-transform-patient-data-consent-using-ai-driven-platform 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/07bc30e3493961b6/astrazeneca-advances-azd0022-novel-oral-krasg12d-inhibitor-in-first-in-human-phase-i-iia-trial 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/af2a019f9f78137c/astrazeneca-advances-two-phase-iii-trials-testing-baxdrostat-combination-therapy-for-cardiovascular-and-kidney-disease 2025-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f0403e6d14f9ef14/harbinger-health-s-blood-based-multi-cancer-test-shows-promise-in-high-risk-obesity-population-at-asco-2025 2025-05-31T22:50:54+00:00 hourly 0.9 https://trial.medpath.com/news/fe16eafd5fc000ca/trinity-life-sciences-partners-with-ontada-to-enhance-real-world-oncology-data-analytics-for-drug-development 2025-05-31T20:44:17+00:00 hourly 0.9 https://trial.medpath.com/news/8aaa0554bb7021f0/napoli-3-post-hoc-analysis-identifies-characteristics-associated-with-long-term-survival-in-metastatic-pancreatic-cancer 2025-05-31T20:44:06+00:00 hourly 0.9 https://trial.medpath.com/news/5edaa1b60ef0f8b7/large-scale-study-reveals-significant-racial-disparities-in-early-onset-colorectal-cancer-diagnosis 2025-05-31T19:51:16+00:00 hourly 0.9 https://trial.medpath.com/news/cf67118d41334c71/facet-life-sciences-partners-with-nucleus-to-advance-radiopharmaceutical-development-through-regulatory-expertise 2025-05-31T16:57:43+00:00 hourly 0.9 https://trial.medpath.com/news/667ed73c217c392a/dual-immunotherapy-combination-significantly-extends-survival-in-advanced-cutaneous-squamous-cell-carcinoma 2025-05-31T16:55:25+00:00 hourly 0.9 https://trial.medpath.com/news/903a8f0239cda2db/ctdna-based-mrd-testing-shows-superior-prognostic-value-in-dlbcl-first-line-treatment 2025-05-31T16:55:09+00:00 hourly 0.9 https://trial.medpath.com/news/5d2a029483e82a55/artera-s-ai-algorithm-identifies-which-prostate-cancer-patients-benefit-from-intensive-therapy-earning-best-of-asco-recognition 2025-05-31T14:54:18+00:00 hourly 0.9 https://trial.medpath.com/news/7acad9e4c79bf788/14-gene-molecular-assay-guides-adjuvant-chemotherapy-in-early-stage-nsclc-reduces-recurrence-risk-by-78 2025-05-31T14:53:55+00:00 hourly 0.9 https://trial.medpath.com/news/41008c40546aa461/transcripta-bio-partners-with-microsoft-research-to-accelerate-ai-driven-disease-gene-discovery 2025-05-31T11:51:06+00:00 hourly 0.9 https://trial.medpath.com/news/cfb90f25054784f5/subtle-medical-expands-ai-powered-mri-enhancement-technology-across-latin-america-with-anvisa-approval-in-brazil 2025-05-31T09:52:56+00:00 hourly 0.9 https://trial.medpath.com/news/d9c5f1818131f971/beam-therapeutics-and-capricor-secure-fda-orphan-drug-designations-for-rare-disease-treatments 2025-05-31T08:55:04+00:00 hourly 0.9 https://trial.medpath.com/news/aa79aace0b22a83a/dual-targeted-car-t-therapy-kite-363-shows-87-response-rate-in-relapsed-b-cell-lymphoma 2025-05-31T08:54:26+00:00 hourly 0.9 https://trial.medpath.com/news/8fbe11e2662bb167/epcoritamab-demonstrates-durable-3-year-remissions-in-relapsed-refractory-large-b-cell-lymphoma 2025-05-31T07:51:50+00:00 hourly 0.9 https://trial.medpath.com/news/95f9585b9e3e8a7d/fda-issues-draft-guidance-to-streamline-color-additive-replacement-in-drug-products 2025-05-31T06:51:58+00:00 hourly 0.9 https://trial.medpath.com/news/b31adddb94894070/circode-biomed-s-hm2002-becomes-world-s-first-circular-rna-drug-to-receive-fda-ind-clearance-for-ischemic-heart-disease 2025-05-31T04:52:55+00:00 hourly 0.9 https://trial.medpath.com/news/08cdfc4ad83eed53/patient-caregiver-preferences-study-reveals-key-treatment-decision-factors-in-alk-nsclc 2025-05-31T03:51:15+00:00 hourly 0.9 https://trial.medpath.com/news/cdf1c122c9cadb46/trump-administration-halts-major-hiv-vaccine-research-programs-despite-scientific-progress 2025-05-31T02:53:54+00:00 hourly 0.9 https://trial.medpath.com/news/a4c62a6f2513fa5e/machine-learning-based-immune-risk-score-outperforms-traditional-methods-in-predicting-colorectal-cancer-outcomes 2025-05-31T02:52:58+00:00 hourly 0.9 https://trial.medpath.com/news/f73b6a2f3917f26f/stage-4-lung-cancer-patient-achieves-complete-response-with-pembrolizumab-immunotherapy 2025-05-31T00:57:29+00:00 hourly 0.9 https://trial.medpath.com/news/a1ee460505c27b84/frontotemporal-dementia-therapeutics-enter-new-era-as-gene-and-antibody-therapies-advance-toward-market 2025-05-31T00:56:28+00:00 hourly 0.9 https://trial.medpath.com/news/2369ef0a624fe14d/her3-dxd-demonstrates-promising-intracranial-activity-in-phase-ii-tuxedo-3-trial-for-brain-metastases 2025-05-31T00:55:04+00:00 hourly 0.9 https://trial.medpath.com/news/2fbb509b649cfabd/sleipnir-multi-arm-platform-receives-ps1-million-to-accelerate-parkinson-s-drug-development-in-norway 2025-05-31T00:54:19+00:00 hourly 0.9 https://trial.medpath.com/news/3249c844e015c18d/meitheal-pharmaceuticals-launches-generic-abraxane-in-us-market-to-address-cancer-treatment-access 2025-05-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b87ba0162b3e2b89/immuron-advances-multi-drug-pipeline-with-fda-submissions-and-clinical-milestones-on-track-for-2025 2025-05-30T23:53:59+00:00 hourly 0.9 https://trial.medpath.com/news/84045819ebfc4cb9/riboscience-s-first-in-class-enpp1-inhibitor-rbs2418-shows-promising-safety-and-efficacy-in-phase-1a-cancer-trial 2025-05-30T23:51:54+00:00 hourly 0.9 https://trial.medpath.com/news/bd8a7ce893987ec8/amgen-s-romiplostim-shows-breakthrough-results-for-chemotherapy-induced-thrombocytopenia-with-nccn-endorsement 2025-05-30T23:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/2a55321fd553d9de/femasys-raises-4-5-million-to-advance-women-s-health-technologies-including-fembloc-birth-control 2025-05-30T22:54:36+00:00 hourly 0.9 https://trial.medpath.com/news/316d7f69cc739c9b/real-world-study-shows-safe-rechallenge-with-trastuzumab-deruxtecan-after-grade-1-interstitial-lung-disease 2025-05-30T22:50:02+00:00 hourly 0.9 https://trial.medpath.com/news/212d4192b2b16dd2/mrpl-secures-us-patent-for-pharmaceutical-intermediate-production-technology 2025-05-30T20:52:40+00:00 hourly 0.9 https://trial.medpath.com/news/80b20f40841394a9/investor-lawsuit-challenges-novartis-1-7-billion-acquisition-of-regulus-therapeutics-over-kidney-disease-drug 2025-05-30T20:52:03+00:00 hourly 0.9 https://trial.medpath.com/news/329a7244d844c3f3/mabwell-s-novel-long-acting-g-csf-drug-mailisheng-receives-nmpa-approval-for-chemotherapy-induced-neutropenia 2025-05-30T20:51:47+00:00 hourly 0.9 https://trial.medpath.com/news/51bed922528b2766/patritumab-deruxtecan-demonstrates-promising-efficacy-in-first-prospective-trial-for-leptomeningeal-metastases 2025-05-30T20:51:36+00:00 hourly 0.9 https://trial.medpath.com/news/10622da350637382/teddy-laboratory-and-labconnect-form-strategic-partnership-to-enhance-global-clinical-trial-services 2025-05-30T20:50:21+00:00 hourly 0.9 https://trial.medpath.com/news/5bf316bf5abc215b/her3-targeted-adc-db-1310-shows-promising-results-in-advanced-solid-tumors-particularly-egfr-mutant-nsclc 2025-05-30T19:53:28+00:00 hourly 0.9 https://trial.medpath.com/news/700ca4c845d46bd9/carlyle-and-sk-capital-complete-3-5-per-share-acquisition-of-gene-therapy-pioneer-bluebird-bio 2025-05-30T19:52:55+00:00 hourly 0.9 https://trial.medpath.com/news/4901432b35d9b100/vizgen-and-hamamatsu-form-strategic-partnership-to-advance-spatial-biology-workflows-for-cancer-research 2025-05-30T18:50:27+00:00 hourly 0.9 https://trial.medpath.com/news/d1818719664a644c/merck-kgaa-s-adc-precemtabart-tocentecan-shows-promising-safety-and-efficacy-in-metastatic-colorectal-cancer-trial 2025-05-30T17:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/5e89523a42d42f62/mapmygenome-acquires-microbiome-insights-to-expand-global-genomics-and-microbiome-research-capabilities 2025-05-30T16:58:11+00:00 hourly 0.9 https://trial.medpath.com/news/b4644336401b173c/car-t-cell-therapy-shows-promise-for-severe-autoimmune-neurological-diseases-in-pioneering-european-studies 2025-05-30T16:56:33+00:00 hourly 0.9 https://trial.medpath.com/news/b3e11776addfc747/novel-car-t-cell-therapy-allo-316-shows-33-response-rate-in-advanced-renal-cell-carcinoma 2025-05-30T16:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/88fea120afe8cc26/cofactor-genomics-ai-powered-rna-platform-shows-300-400-improvement-in-predicting-cancer-immunotherapy-response 2025-05-30T16:55:55+00:00 hourly 0.9 https://trial.medpath.com/news/4739a63d1e54bbf5/universal-car-t-cell-therapy-achieves-91-response-rate-in-aggressive-t-cell-cancers 2025-05-30T16:55:51+00:00 hourly 0.9 https://trial.medpath.com/news/b74dcf3f561755a2/coherus-biosciences-rebrands-as-coherus-oncology-advances-immuno-oncology-pipeline-with-novel-combination-therapies 2025-05-30T16:55:13+00:00 hourly 0.9 https://trial.medpath.com/news/b0c5713d1634d375/bambusa-therapeutics-doses-first-patient-with-bbt002-bispecific-antibody-and-receives-fda-clearance-for-bbt001 2025-05-30T16:55:03+00:00 hourly 0.9 https://trial.medpath.com/news/66a6a369089d4293/polyactiva-secures-40m-series-c-to-advance-revolutionary-glaucoma-implant-technology 2025-05-30T16:54:51+00:00 hourly 0.9 https://trial.medpath.com/news/3e176095f63ca2c6/pancreatic-cancer-pipeline-expands-with-80-companies-advancing-novel-therapies 2025-05-30T16:54:39+00:00 hourly 0.9 https://trial.medpath.com/news/9d05fdc978ec1684/myeloid-therapeutics-reports-first-in-human-data-for-in-vivo-mrna-car-therapies-at-asco-2025 2025-05-30T16:52:44+00:00 hourly 0.9 https://trial.medpath.com/news/98ecf7fffbc18c8b/fda-grants-de-novo-clearance-for-reflow-medical-s-spur-retrievable-stent-system-for-below-the-knee-arterial-disease 2025-05-30T16:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/db241c08ef9d6f69/enterome-s-eo4010-shows-promising-survival-data-in-difficult-to-treat-colorectal-cancer-at-asco-2025 2025-05-30T12:52:49+00:00 hourly 0.9 https://trial.medpath.com/news/50bdebf71d131e5f/u-s-defense-department-partners-with-cepi-to-advance-nipah-virus-monoclonal-antibody-treatment 2025-05-30T12:52:09+00:00 hourly 0.9 https://trial.medpath.com/news/2e1ed3d705d327ef/biolinerx-reports-promising-pancreatic-cancer-trial-results-with-64-response-rate-for-motixafortide-combination 2025-05-30T12:52:05+00:00 hourly 0.9 https://trial.medpath.com/news/26f4c09cafb70754/cspc-pharmaceutical-announces-potential-5-billion-drug-licensing-deals-following-q1-revenue-decline 2025-05-30T12:51:50+00:00 hourly 0.9 https://trial.medpath.com/news/ef8998ee3931cc18/gc-biopharma-s-hunterase-shows-significant-efficacy-in-phase-3-trial-for-hunter-syndrome 2025-05-30T12:50:58+00:00 hourly 0.9 https://trial.medpath.com/news/d6e7a47f65d93843/samsung-bioepis-secures-korean-approval-for-denosumab-biosimilar-xbryk-completing-global-regulatory-trifecta 2025-05-30T12:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/8e4b026298024562/yuhan-corporation-receives-15-million-milestone-from-janssen-following-japan-launch-of-lazertinib-amivantamab-combination-for-egfr-mutated-nsclc 2025-05-30T12:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/1c888fab0e6c653d/china-approves-zanidatamab-as-first-dual-her2-targeted-bispecific-antibody-for-biliary-tract-cancer 2025-05-30T12:50:06+00:00 hourly 0.9 https://trial.medpath.com/news/1357ad54bd75a8f1/marksans-pharma-subsidiary-receives-uk-marketing-authorization-for-metformin-oral-solution 2025-05-30T12:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/9b8766f35794d88d/advanced-renal-cell-carcinoma-pipeline-shows-strong-growth-with-60-therapies-in-development 2025-05-30T10:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/077f94c50c91c44a/outcomes4me-raises-21m-to-expand-ai-driven-cancer-care-platform-globally 2025-05-30T09:53:58+00:00 hourly 0.9 https://trial.medpath.com/news/fb031f74ef13fc7d/cardiosense-launches-seismic-hf-ii-study-to-validate-ai-algorithm-for-heart-failure-management 2025-05-30T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/181143027809d0d5/itepekimab-shows-mixed-results-in-phase-3-copd-trials-meeting-primary-endpoint-in-one-of-two-studies 2025-05-30T08:44:02+00:00 hourly 0.9 https://trial.medpath.com/news/7e29e63571d44d22/qv-bioelectronics-secures-ps1-26-million-to-advance-grace-brain-tumor-device-toward-clinical-trials 2025-05-30T08:44:01+00:00 hourly 0.9 https://trial.medpath.com/news/d119923262bf50dc/illumina-launches-promoterai-tool-to-detect-disease-causing-mutations-in-previously-overlooked-genomic-regions 2025-05-30T08:43:22+00:00 hourly 0.9 https://trial.medpath.com/news/7e2c3354ff40d0b0/iksuda-therapeutics-initiates-first-in-human-trial-of-cd19-targeted-adc-iks03-for-advanced-b-cell-non-hodgkin-lymphoma 2025-05-30T06:55:34+00:00 hourly 0.9 https://trial.medpath.com/news/1b6a7ae68e5634be/astrazeneca-advances-two-experimental-compounds-through-early-stage-clinical-testing 2025-05-30T06:53:11+00:00 hourly 0.9 https://trial.medpath.com/news/c8b25cf7261648d1/astellas-secures-1-4-billion-license-deal-for-novel-cldn18-2-targeting-adc-xnw27011 2025-05-30T05:02:03+00:00 hourly 0.9 https://trial.medpath.com/news/10625c9434d9baa8/uc-davis-clinical-trial-identifies-gene-mutations-as-key-to-treating-aggressive-prostate-cancer 2025-05-30T05:00:20+00:00 hourly 0.9 https://trial.medpath.com/news/3548b1a51e8f7e5a/saudi-arabia-launches-national-biotech-initiative-at-bio-2025-with-strategic-partnerships 2025-05-30T04:59:06+00:00 hourly 0.9 https://trial.medpath.com/news/5bbfb7cb95b9ea07/concurrent-hypertension-and-type-2-diabetes-double-mortality-risk-as-prevalence-surges-in-us-adults 2025-05-30T02:46:56+00:00 hourly 0.9 https://trial.medpath.com/news/4ec611785506abbc/seer-launches-next-generation-proteomics-platform-enabling-unprecedented-20000-sample-cancer-study 2025-05-30T02:46:44+00:00 hourly 0.9 https://trial.medpath.com/news/85fa0a6c07b6f235/comprehensive-supportive-care-emerges-as-critical-component-in-sma-management-beyond-disease-modifying-therapies 2025-05-30T02:46:32+00:00 hourly 0.9 https://trial.medpath.com/news/454d0edfdc2db3e0/made-scientific-expands-princeton-facility-with-12000-sq-ft-gmp-manufacturing-space-for-commercial-cell-therapy-production 2025-05-30T02:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/588ce2703c489a7b/fda-regulatory-framework-provides-multiple-pathways-for-cancer-drug-access-beyond-traditional-approval 2025-05-30T01:58:25+00:00 hourly 0.9 https://trial.medpath.com/news/ecf00b6a5a959ab8/eisai-secures-lenvima-patent-protection-through-2036-in-us-court-victory 2025-05-30T01:47:32+00:00 hourly 0.9 https://trial.medpath.com/news/c002a30dd659a822/clinical-trial-approval-for-hs-10542-capsules-issued-by-nmpa 2025-05-30T00:57:53+00:00 hourly 0.9 https://trial.medpath.com/news/54d94b852d315fd0/delaware-judge-limits-liquidia-s-patent-defense-strategies-in-utc-lung-disease-drug-dispute 2025-05-30T00:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/f79df01ae42a1558/cellares-and-mitsui-fudosan-launch-japan-s-first-automated-car-t-manufacturing-facility 2025-05-30T00:47:25+00:00 hourly 0.9 https://trial.medpath.com/news/8e78752477f42914/parker-institute-showcases-breakthroughs-in-immunotherapy-at-asco-2025-as-ceo-dr 2025-05-30T00:47:21+00:00 hourly 0.9 https://trial.medpath.com/news/8f27376904220b20/acceptance-of-a-new-drug-application-for-naldemedine-a-treatment-for-opioid-induced 2025-05-30T00:46:44+00:00 hourly 0.9 https://trial.medpath.com/news/12b6d445c927ba2a/us-fda-s-prasad-we-will-always-embrace-surrogate-endpoints-citeline-news-insights 2025-05-30T00:45:32+00:00 hourly 0.9 https://trial.medpath.com/news/11da5160267928e4/danaher-partners-with-astrazeneca-to-develop-ai-powered-precision-medicine-diagnostics 2025-05-30T00:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/a8212adfd9f6e027/ai-test-identifies-prostate-cancer-patients-who-benefit-most-from-life-saving-drug-abiraterone 2025-05-30T00:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/37d533bfe8f231d8/uc-davis-phase-2-trial-reveals-circulating-tumor-dna-as-key-biomarker-for-personalized-prostate-cancer-treatment 2025-05-30T00:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/d1219fb1faf36455/invion-s-inv043-photodynamic-therapy-shows-promise-in-phase-i-ii-non-melanoma-skin-cancer-trial 2025-05-30T00:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/e255d154f5967ec9/personalized-treatment-strategies-transform-pulmonary-arterial-hypertension-management-through-multi-pathway-approach 2025-05-30T00:15:02+00:00 hourly 0.9 https://trial.medpath.com/news/202c68c21652b54e/cirm-awards-4-7-million-to-advance-aav-gene-therapy-for-blue-cone-monochromacy 2025-05-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/93981aeca42b2194/remegen-s-telitacicept-receives-approval-in-china-for-generalized-myasthenia-gravis-treatment 2025-05-29T21:49:17+00:00 hourly 0.9 https://trial.medpath.com/news/ca8ea8392de6b4e1/modular-medical-strengthens-board-with-generic-insulin-expert-jeff-goldberg 2025-05-29T21:46:42+00:00 hourly 0.9 https://trial.medpath.com/news/de6a66dc0ca437ce/bioquebec-and-life-sciences-british-columbia-form-strategic-alliance-to-strengthen-canada-s-life-sciences-ecosystem 2025-05-29T20:48:56+00:00 hourly 0.9 https://trial.medpath.com/news/0dad9ab132acf6fd/investigational-monoclonal-antibody-tb006-shows-promise-in-reversing-alzheimer-s-disease-through-galectin-3-targeting 2025-05-29T20:47:32+00:00 hourly 0.9 https://trial.medpath.com/news/d456ad3e22c2c0d0/novel-bag3-expressing-gene-therapy-shows-promise-for-ibm-bioworld 2025-05-29T20:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/b3efee24c9261af2/kenya-slashes-breast-cancer-treatment-costs-by-67-through-roche-partnership 2025-05-29T20:47:15+00:00 hourly 0.9 https://trial.medpath.com/news/072455bef5c9a0dc/neuronata-r-stem-cell-therapy-shows-promise-in-als-subgroup-targets-fda-accelerated-approval 2025-05-29T20:47:11+00:00 hourly 0.9 https://trial.medpath.com/news/3fb097122b5fbb8a/acclaro-medical-secures-23-million-series-b-funding-to-advance-revolutionary-2910-nm-fiber-laser-technology-for-aesthetic-medicine 2025-05-29T20:46:38+00:00 hourly 0.9 https://trial.medpath.com/news/094ca62cb1c9afdb/accelus-secures-growth-financing-to-advance-expandable-spinal-implant-technology 2025-05-29T20:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/57ae334a6a61d799/navigator-medicines-initiates-phase-1b-trial-of-nav-240-bispecific-antibody-for-autoimmune-diseases 2025-05-29T20:14:52+00:00 hourly 0.9 https://trial.medpath.com/news/6649cc16d22e1c66/lyowave-secures-300k-nsf-grant-to-scale-microwave-enhanced-freeze-drying-technology-for-pharmaceutical-manufacturing 2025-05-29T20:14:48+00:00 hourly 0.9 https://trial.medpath.com/news/bb8ffc3f01f18de8/cdmos-expand-end-to-end-services-and-facilities-to-meet-growing-pharmaceutical-manufacturing-demands 2025-05-29T20:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/65a6732bb891c2cd/keros-therapeutics-discontinues-pah-drug-development-following-safety-concerns-in-phase-2-trial 2025-05-29T20:14:43+00:00 hourly 0.9 https://trial.medpath.com/news/b9de263214bb3fa9/skytrofa-receives-australian-approval-as-first-once-weekly-growth-hormone-therapy-for-children 2025-05-29T20:13:25+00:00 hourly 0.9 https://trial.medpath.com/news/5a25f9ab19a5e4d9/rune-labs-and-parkinson-s-foundation-launch-groundbreaking-study-combining-genetic-testing-with-ai-powered-digital-biomarkers 2025-05-29T20:13:14+00:00 hourly 0.9 https://trial.medpath.com/news/70da0c7d47fc4e32/australian-federal-court-streamlines-preliminary-discovery-process-for-pharmaceutical-patent-disputes 2025-05-29T20:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/6bdcfbde57c0f17d/nih-scientists-report-breakthrough-plant-derived-therapy-reduces-intractable-cancer-pain-by-38 2025-05-29T20:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/771147e688d96dbe/mrna-delivery-system-successfully-reactivates-latent-hiv-in-resting-t-cells 2025-05-29T18:51:37+00:00 hourly 0.9 https://trial.medpath.com/news/0e955a82cd46ed1d/teva-unveils-5-billion-growth-strategy-with-five-potential-blockbuster-drugs-in-late-stage-pipeline 2025-05-29T18:50:10+00:00 hourly 0.9 https://trial.medpath.com/news/d8ed7a3901f75763/hedera-dx-secures-eur15-million-series-a-to-expand-decentralized-liquid-biopsy-platform-across-europe 2025-05-29T18:47:54+00:00 hourly 0.9 https://trial.medpath.com/news/be320877d5cc0cf1/cornell-develops-stealthy-lipid-nanoparticles-to-enhance-mrna-vaccine-delivery-and-reduce-immune-side-effects 2025-05-29T18:46:43+00:00 hourly 0.9 https://trial.medpath.com/news/be89ace307f01028/as-the-fda-and-nih-eschew-animal-testing-startup-raises-40-million-for-lab-grown-organs 2025-05-29T17:47:18+00:00 hourly 0.9 https://trial.medpath.com/news/d3e7811ec4ac002c/medicilon-successfully-passes-fda-inspection-strengthening-global-preclinical-r-d-capabilities 2025-05-29T17:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/d5e2ef74aa9cf8b0/sentinel-biotherapeutics-launches-with-novel-il-2-immunotherapy-platform-for-solid-tumors 2025-05-29T16:50:21+00:00 hourly 0.9 https://trial.medpath.com/news/903da7fadaaff50a/cerus-corporation-reports-positive-phase-3-results-for-intercept-blood-system-at-isbt-congress 2025-05-29T16:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/9ec42a925b5ce94e/ludwig-enterprises-develops-non-invasive-breast-cancer-screening-test-using-buccal-cell-mrna-analysis 2025-05-29T16:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/b423f8c522dddd17/dx-vx-advances-universal-covid-19-vaccine-to-phase-2-trials-using-virus-like-particle-platform 2025-05-29T16:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/e2d79054c631def2/cocrystal-pharma-s-cc-42344-shows-1000-fold-greater-potency-than-tamiflu-against-h5n1-avian-influenza 2025-05-29T16:49:12+00:00 hourly 0.9 https://trial.medpath.com/news/342a2a123a8d43d8/bachem-expands-global-manufacturing-network-to-meet-surging-demand-for-peptide-and-oligonucleotide-therapeutics 2025-05-29T16:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/f32752c99a7efcb5/real-world-evidence-guides-extended-dosing-strategies-for-next-generation-anti-vegf-therapies-in-retinal-disease 2025-05-29T16:47:02+00:00 hourly 0.9 https://trial.medpath.com/news/45b80d4b11134d65/biohaven-initiates-pivotal-phase-ii-iii-trial-of-brain-penetrant-tyk2-jak1-inhibitor-bhv-8000-for-early-parkinson-s-disease 2025-05-29T16:19:10+00:00 hourly 0.9 https://trial.medpath.com/news/f1f72a677d785fe1/ochre-bio-strengthens-leadership-with-former-eli-lilly-and-astrazeneca-executive-as-rna-therapeutics-company-expands 2025-05-29T16:18:50+00:00 hourly 0.9 https://trial.medpath.com/news/358a5b27975045de/rona-therapeutics-reports-99-lipoprotein-a-reduction-with-annual-dose-rnai-therapy-rn026 2025-05-29T16:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/843546474417f737/inspira-technologies-accelerates-global-rollout-of-fda-cleared-art100-respiratory-support-system 2025-05-29T16:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/4c17e6b347c82d0f/vima-therapeutics-emerges-with-60m-to-develop-first-oral-therapy-for-dystonia 2025-05-29T16:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/6ac4ebc63eaeba74/fda-approves-7-year-post-market-study-for-brainsee-alzheimer-s-progression-prediction-tool 2025-05-29T16:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/0745f7b3acfc79f2/beyfortus-demonstrates-superior-real-world-efficacy-against-rsv-compared-to-maternal-vaccination 2025-05-29T16:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/7985ccf760088519/lantern-pharma-s-lp-184-demonstrates-significant-survival-benefits-in-pediatric-brain-cancer-models 2025-05-29T16:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/0cb49bcd6122bf1b/uniqure-s-gene-therapy-amt-260-achieves-92-seizure-reduction-in-first-drug-resistant-epilepsy-patient 2025-05-29T16:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/f796a678ff57e4cb/drug-farm-s-df-003-shows-promising-safety-profile-in-phase-1-trial-for-rare-rosah-syndrome 2025-05-29T15:58:33+00:00 hourly 0.9 https://trial.medpath.com/news/e29243b47516fa60/estrella-immunopharma-advances-eb103-artemis-t-cell-therapy-to-second-cohort-in-starlight-1-trial-for-advanced-b-cell-lymphomas 2025-05-29T15:58:03+00:00 hourly 0.9 https://trial.medpath.com/news/a4e4e9403e7e211f/merck-and-daiichi-sankyo-withdraw-fda-application-for-lung-cancer-adc-after-survival-data-disappoints 2025-05-29T14:47:08+00:00 hourly 0.9 https://trial.medpath.com/news/fd0831b9eb2f7bfa/bioaffinity-technologies-secures-patent-for-dual-target-cancer-therapy-using-sirna-against-cd320-and-lrp2-receptors 2025-05-29T14:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/e5d0215ae3335a35/bionical-emas-secures-exclusive-partnership-to-address-critical-european-fluorouracil-shortage 2025-05-29T14:01:28+00:00 hourly 0.9 https://trial.medpath.com/news/c6d37ae2bd7b55a0/iveena-submits-ind-application-for-novel-non-atropine-eye-drop-to-treat-pediatric-myopia 2025-05-29T14:00:57+00:00 hourly 0.9 https://trial.medpath.com/news/5594e2cca9f47a0d/iveena-announces-ind-submission-to-the-u-s-fda-for-a-phase-2 2025-05-29T14:00:55+00:00 hourly 0.9 https://trial.medpath.com/news/abec43cf879eca81/kyzatrex-oral-testosterone-therapy-achieves-96-efficacy-rate-in-phase-3-trials-for-hypogonadism-treatment 2025-05-29T13:45:16+00:00 hourly 0.9 https://trial.medpath.com/news/5224d1dc4832f1df/pfizer-faces-legal-challenges-as-study-links-depo-provera-to-increased-meningioma-risk 2025-05-29T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/dc218aa909156b43/sarvodaya-hospital-becomes-first-in-india-to-offer-terbium-161-psma-therapy-for-advanced-prostate-cancer 2025-05-29T12:39:53+00:00 hourly 0.9 https://trial.medpath.com/news/f230a86009677461/excyte-doses-first-patient-with-yk012-world-s-first-t-cell-engager-for-primary-membranous-nephropathy 2025-05-29T12:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/33079886422c99e4/daiichi-sankyo-and-merck-withdraw-patritumab-deruxtecan-bla-after-phase-3-trial-fails-to-meet-overall-survival-endpoint 2025-05-29T12:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/45073df409f0683b/genor-biopharma-secures-nmpa-approval-for-lerociclib-cdk4-6-inhibitor-in-advanced-breast-cancer 2025-05-29T12:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/3786f31a23a5b7f4/china-s-mazdutide-achieves-breakthrough-as-world-s-first-gcg-glp-1-dual-receptor-agonist-for-weight-loss 2025-05-29T12:38:07+00:00 hourly 0.9 https://trial.medpath.com/news/083eded5f98792dd/court-rulings-shape-patent-safe-harbor-provision-s-impact-on-pharmaceutical-development 2025-05-29T08:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/657001a398f9a5c3/disc-medicine-presents-comprehensive-hematology-portfolio-data-at-eha-2025-congress 2025-05-29T05:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/0b100606c08f1590/oncology-clinical-trials-embrace-ai-and-digital-solutions-to-enhance-patient-centric-approaches 2025-05-29T04:46:04+00:00 hourly 0.9 https://trial.medpath.com/news/9f61b23a77de5ecd/noxopharm-receives-ethics-approval-for-first-in-human-trial-of-sof-skn-in-cutaneous-lupus 2025-05-29T04:40:13+00:00 hourly 0.9 https://trial.medpath.com/news/2d92545f7b59087d/innovent-initiates-phase-3-trial-of-picankibart-for-psoriasis-patients-with-inadequate-il-17-response 2025-05-29T04:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/523677c1d8fd2ab0/implantable-biobattery-achieves-99-6-tumor-reduction-in-breakthrough-drug-free-cancer-treatment 2025-05-29T04:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/6f9dac528c3e9037/japan-launches-world-s-first-clinical-trials-for-artificial-blood-in-2025 2025-05-29T04:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/531d4659483921a6/pharmacists-lead-implementation-of-advanced-cell-and-gene-therapies-across-major-health-systems 2025-05-29T03:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/c35473e6e1c5c754/iambic-therapeutics-showcases-ai-driven-drug-discovery-platform-at-multiple-investor-conferences 2025-05-29T02:42:49+00:00 hourly 0.9 https://trial.medpath.com/news/c50674aaf8423101/precision-medicine-approaches-transform-bronchiectasis-management-as-research-centers-expand-nationwide 2025-05-29T02:42:47+00:00 hourly 0.9 https://trial.medpath.com/news/4e2d893d59f24348/ultra-processed-foods-linked-to-increased-asthma-and-allergy-risk-in-children-research-shows 2025-05-29T02:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/5e5364324a4964a8/oral-ritlecitinib-combined-with-phototherapy-shows-enhanced-repigmentation-in-nonsegmental-vitiligo 2025-05-29T02:42:38+00:00 hourly 0.9 https://trial.medpath.com/news/5248a52005dde438/epivax-appoints-dr-vibha-jawa-as-chief-scientific-officer-to-lead-immunogenicity-strategy 2025-05-29T02:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/5e2c9df61f0c0a65/first-line-treatment-options-for-metastatic-pancreatic 2025-05-29T02:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/2117502ff3b75724/global-study-links-covid-19-infection-and-adenoviral-vaccines-to-guillain-barre-syndrome-risk-clears-mrna-vaccines 2025-05-29T00:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/edc5fe0b7e83e699/trump-administration-cancels-590-million-moderna-bird-flu-vaccine-contract-amid-mrna-technology-review 2025-05-29T00:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/0290c0bc1707017f/supernus-faces-generic-competition-as-third-parties-file-anda-challenges-for-adhd-drug-qelbree 2025-05-29T00:47:44+00:00 hourly 0.9 https://trial.medpath.com/news/fbb72483b56a5a58/eisai-and-merck-secure-patent-victory-blocking-lenvima-generic-until-2036 2025-05-29T00:47:41+00:00 hourly 0.9 https://trial.medpath.com/news/ea2c8eb79a657f73/fda-approved-menopause-drug-duavee-shows-promise-for-breast-cancer-prevention-in-phase-2-trial 2025-05-29T00:47:23+00:00 hourly 0.9 https://trial.medpath.com/news/8d29d40e53247f32/ausperbio-secures-50-million-series-b-funding-to-advance-hepatitis-b-functional-cure-candidate-ahb-137 2025-05-29T00:46:44+00:00 hourly 0.9 https://trial.medpath.com/news/bb016e878c7c24cc/maia-biotechnology-raises-695000-in-private-placement-to-fund-phase-ii-thio-101-cancer-trial 2025-05-29T00:46:33+00:00 hourly 0.9 https://trial.medpath.com/news/13612f3338d11b48/coremap-receives-fda-ide-approval-to-expand-novel-atrial-fibrillation-mapping-technology-study-to-u-s 2025-05-29T00:46:15+00:00 hourly 0.9 https://trial.medpath.com/news/09d65e225f038fcc/eton-pharmaceuticals-receives-fda-approval-for-khindivi-first-hydrocortisone-oral-solution-for-pediatric-adrenal-insufficiency 2025-05-29T00:45:52+00:00 hourly 0.9 https://trial.medpath.com/news/333d43ee666d97e1/fda-approves-first-in-class-trpm8-receptor-agonist-tryptyr-for-dry-eye-disease-treatment 2025-05-29T00:45:51+00:00 hourly 0.9 https://trial.medpath.com/news/a4aaecb8e7778524/armored-anti-gpc3-jw-004-shows-increased-potency-against-hcc-bioworld 2025-05-29T00:45:35+00:00 hourly 0.9 https://trial.medpath.com/news/85a7e355d76477f9/ira-biosimilar-incentives-drive-measurable-uptake-in-us-healthcare-facilities 2025-05-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ebec8839ff9f4bc/charles-river-and-chdi-foundation-extend-multi-decade 2025-05-28T22:45:21+00:00 hourly 0.9 https://trial.medpath.com/news/84712a5dcb45133c/cessatech-raises-dkk-14-8-million-to-accelerate-u-s-commercial-launch-of-pediatric-pain-treatment-ct001 2025-05-28T22:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/cc5a8681818070eb/javara-secures-series-c-funding-to-expand-community-based-clinical-trial-access-into-oncology-and-cns 2025-05-28T21:46:31+00:00 hourly 0.9 https://trial.medpath.com/news/43dd9bbf058c92dc/wacker-biotech-and-expression-manufacturing-form-strategic-partnership-to-accelerate-lentiviral-gene-therapy-development 2025-05-28T21:45:47+00:00 hourly 0.9 https://trial.medpath.com/news/afc6f01a8ba0d2f6/canada-launches-first-home-based-cancer-immunotherapy-trial-using-subcutaneous-injection 2025-05-28T20:49:50+00:00 hourly 0.9 https://trial.medpath.com/news/9c701f9b5fc5e24b/therapeutic-plasma-exchange-combined-with-immunoglobulin-reduces-biological-age-by-2-6-years-in-clinical-trial 2025-05-28T20:49:31+00:00 hourly 0.9 https://trial.medpath.com/news/c8d41a4c5c4d86cf/researchers-achieve-first-ever-production-of-human-dnase1-in-yeast-offering-cost-effective-alternative-to-hamster-cell-manufacturing 2025-05-28T20:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/7f934edb7f737c99/texas-approves-50-million-for-ibogaine-research-initiative-largest-state-funded-psychedelic-program-in-us-history 2025-05-28T20:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/b5a3ac5381fab04b/wave-life-sciences-announces-appointment-of-dr-christopher-wright-as-chief-medical-officer 2025-05-28T20:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/efc7cc091763c706/stereotactic-radiation-therapy-shows-superior-quality-of-life-benefits-over-hippocampal-avoidance-wbrt-in-brain-metastases-trial 2025-05-28T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/42b7d82e2bcf9eb6/hyperfine-receives-fda-clearance-for-ai-enhanced-portable-mri-software-approaching-conventional-scanner-quality 2025-05-28T19:44:37+00:00 hourly 0.9 https://trial.medpath.com/news/7571bb6cf367f2e3/enthera-pharmaceuticals-announces-publication-in-the-journal-of-clinical-investigation-supporting-the-clinical-development-of-ebrasodebart 2025-05-28T18:47:01+00:00 hourly 0.9 https://trial.medpath.com/news/2665b0902244a95f/scientists-discover-critical-window-for-in-vivo-gene-therapy-in-newborns 2025-05-28T18:46:58+00:00 hourly 0.9 https://trial.medpath.com/news/7466199a2e7ac110/xoma-royalty-acquires-30-million-mezagitamab-rights-from-bioinvent-as-anti-cd38-antibody-advances-to-phase-3 2025-05-28T18:46:27+00:00 hourly 0.9 https://trial.medpath.com/news/a598a2a073619b8b/egypt-s-holdipharma-forms-strategic-joint-venture-with-us-partner-to-enter-north-american-and-european-markets 2025-05-28T18:45:40+00:00 hourly 0.9 https://trial.medpath.com/news/0d0cfae0790a71ce/bora-pharmaceuticals-expands-sterile-fill-finish-capacity-in-baltimore-to-meet-growing-demand-for-high-value-drug-products 2025-05-28T17:55:30+00:00 hourly 0.9 https://trial.medpath.com/news/371e76dcafffba1f/boston-scientific-discontinues-acurate-tavr-program-after-clinical-trial-failure 2025-05-28T17:53:56+00:00 hourly 0.9 https://trial.medpath.com/news/e827d2260fed1121/proteinqure-secures-11m-series-a-to-advance-first-ai-designed-peptide-therapeutic-for-triple-negative-breast-cancer 2025-05-28T17:53:16+00:00 hourly 0.9 https://trial.medpath.com/news/845a24965b136af9/cancer-drug-combination-extends-mouse-lifespan-by-30-in-aging-research-breakthrough 2025-05-28T17:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/666939402d826e9f/aphios-receives-u-s-patent-allowance-for-room-temperature-stable-single-shot-mrna-covid-19-vaccine 2025-05-28T16:51:29+00:00 hourly 0.9 https://trial.medpath.com/news/8eb2df4115bbd8d2/ai-driven-clinical-decision-support-system-accelerates-bacteremia-treatment-by-29-hours-in-groundbreaking-study 2025-05-28T16:51:17+00:00 hourly 0.9 https://trial.medpath.com/news/d7eab3da63dfd10c/carb-x-awards-debiopharm-additional-12-3-million-to-advance-novel-antibiotic-debio-1453-against-drug-resistant-gonorrhea 2025-05-28T16:51:16+00:00 hourly 0.9 https://trial.medpath.com/news/271a22f83ee85c76/monarch-therapeutics-and-snap-biosciences-partner-to-advance-car-nk-cell-therapy-with-small-molecule-adaptor-technology 2025-05-28T16:50:18+00:00 hourly 0.9 https://trial.medpath.com/news/9808997796008dc7/hillstar-bio-strengthens-leadership-team-with-key-appointments-to-advance-precision-immunotherapy-pipeline 2025-05-28T16:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/9baf451e03ab1d06/fda-aligns-with-olema-on-90mg-palazestrant-dose-for-phase-3-breast-cancer-trials 2025-05-28T16:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/6e3b3f927b664b88/octapharma-s-panzyga-shows-mixed-results-in-phase-3-pans-trial-achieves-significant-secondary-endpoint 2025-05-28T16:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/471b2fec1cb04333/archeus-technologies-and-warf-partner-to-advance-novel-prostate-cancer-radiopharmaceutical-art-101-into-phase-1-trials 2025-05-28T16:49:25+00:00 hourly 0.9 https://trial.medpath.com/news/4556aec0afef65f9/veru-s-enobosarm-shows-improved-safety-profile-in-combination-with-wegovy-for-muscle-preserving-obesity-treatment 2025-05-28T16:49:21+00:00 hourly 0.9 https://trial.medpath.com/news/c16683069142b095/tpn-101-selected-for-healey-als-platform-trial-following-promising-phase-2-results-in-c9orf72-related-als 2025-05-28T16:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/a057441fcd155214/fda-clears-phase-1b-trial-for-novel-nectin-4-targeted-radiopharmaceutical-aky-1189-across-multiple-cancer-types 2025-05-28T16:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/24e474edd71ca3b1/lumanity-and-parker-institute-form-strategic-alliance-to-accelerate-cancer-immunotherapy-development 2025-05-28T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/69060e2846cfba12/genflow-biosciences-advances-sirt6-gene-therapy-pipeline-with-strategic-partnerships-and-patent-expansion 2025-05-28T16:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/6f24bfb8e727f022/incannex-eliminates-347-million-share-dilution-ahead-of-pivotal-sleep-apnea-drug-trial-results 2025-05-28T16:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/096333c9e06b28fa/enveric-biosciences-eb-003-shows-statistically-significant-antidepressant-effects-in-preclinical-depression-model 2025-05-28T16:46:56+00:00 hourly 0.9 https://trial.medpath.com/news/9cf722d5cc85533b/collplant-advances-regenerative-breast-implant-technology-with-promising-preclinical-results 2025-05-28T16:46:25+00:00 hourly 0.9 https://trial.medpath.com/news/281fa9bd78061301/tq-therapeutics-acquires-juno-gmbh-to-advance-decentralized-cell-therapy-platform 2025-05-28T16:46:23+00:00 hourly 0.9 https://trial.medpath.com/news/8e7fb1b53dc70cf4/enveda-s-ai-discovered-anti-inflammatory-env-294-clears-phase-1-safety-trial-advances-to-atopic-dermatitis-study 2025-05-28T16:46:19+00:00 hourly 0.9 https://trial.medpath.com/news/2768931d773761c9/biohaven-s-novel-adcs-show-promising-early-clinical-results-with-topoix-payload-technology 2025-05-28T16:21:11+00:00 hourly 0.9 https://trial.medpath.com/news/3a39f93a99f0ce7a/debra-research-and-dermaliq-partner-to-develop-touchless-drug-delivery-for-epidermolysis-bullosa 2025-05-28T16:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/3d77bf8c941beec3/biostem-technologies-receives-patent-allowances-for-novel-fenestrated-placental-allografts 2025-05-28T16:20:25+00:00 hourly 0.9 https://trial.medpath.com/news/05c6888987038b8b/regeneron-partners-with-telesis-bio-to-deploy-revolutionary-dna-synthesis-platform-for-accelerated-drug-development 2025-05-28T16:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/d889aa948d216d74/radyus-research-and-eurofins-cdmo-alphora-form-strategic-partnership-to-accelerate-early-stage-drug-development 2025-05-28T16:19:58+00:00 hourly 0.9 https://trial.medpath.com/news/363ea0fd957e725e/nuclera-and-cytiva-partnership-reduces-protein-characterization-timeline-from-months-to-five-days 2025-05-28T16:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/fc676aa73987fcd7/redeye-synact-pharma-q1-2025-new-phase-ii-study-in-dengue-fever-tradingview 2025-05-28T16:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/c232c05017a7ad8d/distalmotion-receives-fda-510-k-clearance-for-dexter-robotic-surgery-system-in-cholecystectomy 2025-05-28T16:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/b16cb83a5412fade/alvotech-and-advanz-pharma-expand-13-8-billion-biosimilar-partnership-with-three-new-candidates 2025-05-28T16:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/a327c8962cf3e798/aspire-biopharma-holdings-inc-provides-development-update-on-buzz-bomb-tm-usa-today 2025-05-28T16:17:15+00:00 hourly 0.9 https://trial.medpath.com/news/8cd1186f69871a38/tumor-infiltrating-lymphocytes-emerge-as-key-biomarkers-for-nsclc-immunotherapy-response 2025-05-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/857ad5c379f43733/australian-developed-pill-could-ease-distressing-behaviours-in 2025-05-28T15:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/ff408159a94da13c/gsk-s-tebipenem-hbr-phase-iii-trial-stopped-early-for-efficacy-in-complicated-uti-treatment 2025-05-28T15:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/722649f0fa00e12b/german-radiopharmaceutical-biotech-itm-secures-262-5m-debt-financing-to-advance-cancer-treatment-technologies 2025-05-28T14:44:42+00:00 hourly 0.9 https://trial.medpath.com/news/44843b9bccd20651/medable-launches-digital-platform-to-address-20-dropout-rate-in-cell-and-gene-therapy-long-term-follow-up-studies 2025-05-28T14:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/24c0058d358beca9/phase-2-trial-evaluates-host-directed-therapies-for-rifampicin-resistant-tuberculosis 2025-05-28T12:41:08+00:00 hourly 0.9 https://trial.medpath.com/news/e0ee8bd4ec540ae9/pimicotinib-achieves-54-response-rate-in-phase-3-trial-for-rare-joint-tumor 2025-05-28T12:40:51+00:00 hourly 0.9 https://trial.medpath.com/news/a69a609cc039c8c5/strand-therapeutics-reports-promising-phase-1-data-for-novel-mrna-cancer-therapy-stx-001 2025-05-28T12:40:45+00:00 hourly 0.9 https://trial.medpath.com/news/a4b12ae306a8be3b/st-george-s-hospital-achieves-majority-remission-rate-in-first-car-t-cell-therapy-patients 2025-05-28T12:40:40+00:00 hourly 0.9 https://trial.medpath.com/news/44c92e364ecac331/alamar-biosciences-partners-with-scilifelab-to-advance-precision-proteomics-for-early-disease-detection 2025-05-28T12:40:03+00:00 hourly 0.9 https://trial.medpath.com/news/07c3513093dd6cde/ttf-1-biomarker-predicts-survival-outcomes-for-kras-inhibitor-sotorasib-in-lung-cancer 2025-05-28T12:40:02+00:00 hourly 0.9 https://trial.medpath.com/news/03f1c2821848f68a/novartis-launches-7-tender-offer-for-regulus-therapeutics-with-additional-regulatory-milestone-payment 2025-05-28T12:39:19+00:00 hourly 0.9 https://trial.medpath.com/news/c11afe19747e193e/arcticzymes-and-austrian-centre-extend-partnership-to-advance-bionanoparticle-purification-for-gene-therapies 2025-05-28T12:38:06+00:00 hourly 0.9 https://trial.medpath.com/news/da014623d98c548a/british-columbia-biosimilar-policy-shows-no-impact-on-healthcare-utilization-for-inflammatory-arthritis-patients 2025-05-28T12:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/ecaeb854fa4de3ae/sobi-to-present-clinical-data-on-rare-disease-therapies-at-eular-2025 2025-05-28T12:37:52+00:00 hourly 0.9 https://trial.medpath.com/news/18c150af49b75241/efficacy-and-safety-of-a-house-dust-mites-allergoid-in-patients-with-allergic-rhinitis 2025-05-28T12:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/6ed153d3e309affa/bd-launches-xtract-registry-to-evaluate-real-world-outcomes-of-rotarex-atherectomy-system-in-peripheral-artery-disease 2025-05-28T12:37:49+00:00 hourly 0.9 https://trial.medpath.com/news/73f986e40dc7afa8/french-biotech-kyron-bio-raises-eur5-5m-to-advance-glycan-controlled-antibody-therapeutics 2025-05-28T08:44:32+00:00 hourly 0.9 https://trial.medpath.com/news/ecb1786a0b3a7cfc/blinatumomab-combination-therapy-wins-prestigious-trial-of-the-year-award-for-pediatric-leukemia-breakthrough 2025-05-28T08:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/3066907cd66f184e/singapore-s-ebc-129-antibody-drug-conjugate-receives-fda-fast-track-designation-for-pancreatic-cancer-treatment 2025-05-28T08:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/9978f1d5508a6617/portal-access-secures-7m-series-a-to-advance-next-generation-chemotherapy-port-through-fda-approval 2025-05-28T08:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/e096b1d82e05a1d5/biogen-partners-with-city-therapeutics-to-develop-rnai-therapies-for-central-nervous-system-diseases 2025-05-28T04:58:16+00:00 hourly 0.9 https://trial.medpath.com/news/096119bb2b5bc1d7/japan-s-intellectual-property-high-court-orders-y-21-7-billion-patent-infringement-payout-for-toray-s-anti-itch-drug 2025-05-28T04:43:22+00:00 hourly 0.9 https://trial.medpath.com/news/513213937a7bdea8/olympus-receives-fda-clearance-for-advanced-edof-endoscopy-technology-to-enhance-gi-lesion-detection 2025-05-28T04:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/f8fdcc6ee51053b6/singapore-ai-platform-cuts-clinical-audit-time-by-90-partners-with-roche-for-clinical-trial-acceleration 2025-05-28T04:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/4487519abd8e8d0a/oncologists-address-diagnostic-challenges-and-treatment-advances-in-nasopharyngeal-cancer 2025-05-28T03:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/c6355caa9ea47f36/valneva-advances-lyme-disease-vaccine-vla15-with-pfizer-partnership-as-phase-3-data-expected-by-end-of-2025 2025-05-28T03:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/415264d6a71af184/community-oncology-practices-expand-access-to-car-t-and-bispecific-therapies-as-workforce-challenges-persist 2025-05-28T02:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/89c4072dea046a08/acadia-pharmaceuticals-appoints-bristol-myers-squibb-veteran-to-lead-rare-disease-commercial-strategy 2025-05-28T02:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/1fd716c35cb86749/salvia-raises-60m-for-neuromodulation-migraine-system 2025-05-28T01:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/1592eecad0c7edf8/five-year-sequoia-data-confirms-zanubrutinib-s-long-term-efficacy-in-high-risk-cll-sll-patients 2025-05-28T00:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/c6e026371edf12cf/phase-3-trial-advances-imetelstat-as-potential-game-changer-for-jak-inhibitor-resistant-myelofibrosis 2025-05-28T00:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/18a548ebab9689e4/fda-grants-fast-track-designation-to-teva-s-tev-53408-for-celiac-disease-treatment 2025-05-28T00:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/c62bd353afd052d2/ai-driven-solutions-transform-pharmaceutical-supply-chain-management-amid-growing-disruptions 2025-05-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9c8d72dd57893939/scientists-develop-in-vivo-car-t-cell-engineering-to-reduce-cancer-treatment-costs-and-complexity 2025-05-27T23:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/013243aa7ecf8ea4/seres-therapeutics-ser-155-shows-promise-for-immune-recovery-in-stem-cell-transplant-patients 2025-05-27T20:57:33+00:00 hourly 0.9 https://trial.medpath.com/news/0cabc463a54c4033/hibercell-completes-dose-escalation-phase-for-hc-7366-plus-belzutifan-in-advanced-kidney-cancer-trial 2025-05-27T20:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/44b6a6f53eb85c1c/vancouver-general-hospital-launches-canada-s-first-dedicated-inpatient-clinical-trials-unit-for-blood-cancer-therapies 2025-05-27T20:38:12+00:00 hourly 0.9 https://trial.medpath.com/news/fe4b887926192ee5/bcli-receives-regulatory-clearance-to-initiate-phase-3b-als-trial-smartkarma 2025-05-27T20:38:03+00:00 hourly 0.9 https://trial.medpath.com/news/ced1afda345adf80/ovarian-cancer-survival-disparities-revealed-among-asian-american-subgroups-despite-overall-lower-mortality-rates 2025-05-27T20:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/9455c6e0e32e686e/celecor-completes-phase-3-trial-of-novel-pre-hospital-heart-attack-drug-disaggpro 2025-05-27T20:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/5544a1ba815eb250/saga-diagnostics-launches-pathlight-mrd-test-with-100-sensitivity-for-early-breast-cancer-detection 2025-05-27T20:17:30+00:00 hourly 0.9 https://trial.medpath.com/news/c97f03501297db28/neuralink-secures-600m-funding-round-valuation-soars-to-9b-following-fda-breakthrough-designation 2025-05-27T20:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/719d7ab77c7925f0/guided-therapeutics-secures-700000-order-for-luviva-cervical-cancer-screening-systems-in-china 2025-05-27T20:17:15+00:00 hourly 0.9 https://trial.medpath.com/news/1657be0242262c12/anx-robotica-receives-fda-510-k-clearance-for-motilicap-and-motiliscan-gi-motility-monitoring-system 2025-05-27T20:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/81987f47d4ce09a5/pearl-achieves-historic-fda-clearance-for-first-ai-platform-supporting-both-2d-and-3d-dental-imaging-analysis 2025-05-27T20:16:45+00:00 hourly 0.9 https://trial.medpath.com/news/f5e2f4eb1c77446c/imlifidase-shows-rapid-functional-recovery-in-phase-2-guillain-barre-syndrome-trial 2025-05-27T19:45:17+00:00 hourly 0.9 https://trial.medpath.com/news/ef9ff3700b51d860/drug-farm-and-amoytop-partner-on-first-in-class-alpk1-agonist-df-006-for-hepatitis-b-and-liver-cancer-treatment 2025-05-27T18:44:27+00:00 hourly 0.9 https://trial.medpath.com/news/0984c18a0c0aea6c/hiv-drug-lamivudine-shows-promise-as-oral-treatment-for-diabetic-macular-edema-in-clinical-trial 2025-05-27T17:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/28baf1711c9adedb/altamira-therapeutics-partners-with-undisclosed-company-to-advance-circular-rna-delivery-platform 2025-05-27T17:00:51+00:00 hourly 0.9 https://trial.medpath.com/news/3f6abf9f650dd12d/brooklyn-health-raises-6-5m-to-transform-cns-clinical-trial-measurement-with-ai-powered-platform 2025-05-27T17:00:29+00:00 hourly 0.9 https://trial.medpath.com/news/47783a5b932ee160/immunitybio-partners-with-saudi-arabia-to-bring-fda-approved-cancer-bioshield-platform-to-middle-east 2025-05-27T16:58:26+00:00 hourly 0.9 https://trial.medpath.com/news/205523bc099b6fe7/vgenomics-partners-with-dr-shroff-s-eye-hospital-to-validate-ai-powered-tear-biomarker-for-early-keratoconus-detection 2025-05-27T16:57:27+00:00 hourly 0.9 https://trial.medpath.com/news/f54acb5b28b8bee1/salvia-bioelectronics-raises-60m-series-b-to-advance-breakthrough-neuromodulation-therapy-for-chronic-migraine 2025-05-27T16:56:04+00:00 hourly 0.9 https://trial.medpath.com/news/51bfce3e279d362d/lexeo-therapeutics-secures-80m-financing-to-advance-genetic-heart-disease-therapies 2025-05-27T16:56:02+00:00 hourly 0.9 https://trial.medpath.com/news/923e98dabbc4b12a/storm-therapeutics-initiates-first-in-class-rna-modification-therapy-combination-trial-with-checkpoint-inhibitor 2025-05-27T16:55:57+00:00 hourly 0.9 https://trial.medpath.com/news/d5d731efafce5e04/novartis-expands-strategic-partnership-with-shanghai-pharma-to-accelerate-ophthalmic-drug-distribution-in-china 2025-05-27T16:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/684524374471f216/federal-courts-block-msn-laboratories-early-launch-of-generic-entresto-until-july-2025 2025-05-27T16:54:56+00:00 hourly 0.9 https://trial.medpath.com/news/5c645c66c71ac9de/eli-lilly-acquires-siteone-therapeutics-for-up-to-1-billion-to-advance-non-opioid-pain-treatment 2025-05-27T16:54:31+00:00 hourly 0.9 https://trial.medpath.com/news/d335c23bda4bf86c/bioivt-and-handok-biotech-form-exclusive-partnership-to-expand-biospecimen-access-in-south-korea 2025-05-27T16:54:17+00:00 hourly 0.9 https://trial.medpath.com/news/a4cf5556f942a169/non-invasive-ear-stimulation-shows-promise-for-osteoarthritis-knee-pain-relief 2025-05-27T16:53:07+00:00 hourly 0.9 https://trial.medpath.com/news/6ea2a82b2b22217d/john-snow-labs-acquires-wisecube-to-enhance-medical-ai-with-billion-scale-knowledge-graphs 2025-05-27T16:53:05+00:00 hourly 0.9 https://trial.medpath.com/news/b5a48ff6b8085988/iolyx-therapeutics-reports-positive-phase-2-results-for-ilyx-002-in-autoimmune-associated-dry-eye-disease 2025-05-27T16:53:03+00:00 hourly 0.9 https://trial.medpath.com/news/3318388e6ecf2564/maxiom-launches-ai-powered-health-coach-platform-enters-clinical-trials-to-validate-performance-against-human-experts 2025-05-27T16:52:19+00:00 hourly 0.9 https://trial.medpath.com/news/949f322d67a2eab0/pillar-biosciences-secures-34-5m-funding-round-led-by-illumina-to-advance-ngs-cancer-testing-platform 2025-05-27T16:52:17+00:00 hourly 0.9 https://trial.medpath.com/news/9bd21469ec90ebe2/neuropace-s-rns-system-shows-promise-in-idiopathic-generalized-epilepsy-trial-despite-mixed-primary-endpoint-results 2025-05-27T16:52:11+00:00 hourly 0.9 https://trial.medpath.com/news/cb61c08226c760b7/grin-therapeutics-secures-140m-series-d-and-global-partnership-with-angelini-pharma-for-radiprodil-development 2025-05-27T16:52:09+00:00 hourly 0.9 https://trial.medpath.com/news/81746b83c24b3d36/syndeio-biosciences-launches-with-90m-to-target-synaptic-dysfunction-in-alzheimer-s-and-depression 2025-05-27T16:51:59+00:00 hourly 0.9 https://trial.medpath.com/news/6505c9ef60a31d57/curifylabs-secures-eur6-7m-to-automate-personalized-medicine-manufacturing-with-ai-driven-platform 2025-05-27T16:51:22+00:00 hourly 0.9 https://trial.medpath.com/news/1fa0e22bd4cda3db/palvella-therapeutics-appoints-rare-disease-commercial-expert-ashley-kline-as-chief-commercial-officer 2025-05-27T16:50:43+00:00 hourly 0.9 https://trial.medpath.com/news/cc05c823480972b7/abbott-s-tendyne-system-receives-fda-approval-as-first-transcatheter-mitral-valve-replacement-for-severe-calcification 2025-05-27T16:50:35+00:00 hourly 0.9 https://trial.medpath.com/news/d22cde0dd03cd2ef/fda-expands-menquadfi-meningococcal-vaccine-approval-to-include-infants-as-young-as-6-weeks 2025-05-27T16:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/33d9c6eb9330afc3/teva-and-biolojic-design-launch-ind-enabling-studies-for-dual-target-bd9-antibody-in-inflammatory-diseases 2025-05-27T16:50:08+00:00 hourly 0.9 https://trial.medpath.com/news/56d746c3a8cef6e4/eu-to-track-decentralized-clinical-trials-in-ctis-to-support-innovation-pink-sheet 2025-05-27T16:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/627af1742ef771f0/biogen-partners-with-city-therapeutics-in-1-billion-rnai-collaboration-for-cns-diseases 2025-05-27T15:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/74e6845a5391afbb/viatris-launches-first-clozapine-orally-disintegrating-tablet-in-canada-for-treatment-resistant-schizophrenia 2025-05-27T15:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/adfd54d55edc31f9/apotex-launches-first-generic-nilotinib-in-us-with-180-day-market-exclusivity 2025-05-27T15:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/e194a75553055e42/pyc-therapeutics-advances-pyc-003-to-second-cohort-in-phase-ia-trial-for-polycystic-kidney-disease 2025-05-27T15:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/ec21b586478faf0f/use-of-glp-1-drugs-to-treat-overweight-or-obesity-increased-587-percent-from-2019-to-2024-according-to-new-fair-health-study 2025-05-27T13:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/349a5de072b8c034/rheacell-and-aop-health-partner-to-advance-stem-cell-therapy-for-epidermolysis-bullosa-and-chronic-venous-wounds 2025-05-27T12:57:51+00:00 hourly 0.9 https://trial.medpath.com/news/c14148c35aaf781c/honeywell-acquires-johnson-matthey-s-catalyst-technologies-for-ps1-8-billion-to-expand-clean-energy-solutions 2025-05-27T12:41:33+00:00 hourly 0.9 https://trial.medpath.com/news/71d686bb8d65ecba/ku-leuven-spin-off-hemastatx-develops-first-therapy-targeting-root-cause-of-severe-bleeding-disorder 2025-05-27T12:41:28+00:00 hourly 0.9 https://trial.medpath.com/news/0b87b2f7a7e28e07/glycoera-secures-130m-series-b-to-advance-precision-protein-degrader-for-autoimmune-diseases 2025-05-27T12:41:22+00:00 hourly 0.9 https://trial.medpath.com/news/86452c7c67c48f2d/fda-places-clinical-hold-on-rocket-pharmaceuticals-danon-disease-gene-therapy-after-patient-death 2025-05-27T12:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/fd6b07cd0c73ef4a/epitopea-s-cryptomap-platform-identifies-novel-immunotherapy-targets-in-melanoma-and-nsclc 2025-05-27T12:40:42+00:00 hourly 0.9 https://trial.medpath.com/news/95d49ca0c1b4457a/kahr-bio-s-dsp107-combination-shows-promise-in-microsatellite-stable-colorectal-cancer-at-asco-2025 2025-05-27T12:40:40+00:00 hourly 0.9 https://trial.medpath.com/news/315ca6b72eb5779c/invivyd-s-pemgarda-shows-84-covid-19-prevention-efficacy-in-landmark-phase-3-trial 2025-05-27T12:40:35+00:00 hourly 0.9 https://trial.medpath.com/news/c8fd3acab32eb030/bostongene-presents-six-ai-driven-cancer-research-studies-at-2025-asco-annual-meeting 2025-05-27T12:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/218e6e8d71966a23/phanes-therapeutics-doses-first-patient-with-anti-cd73-antibody-mavrostobart-in-combination-therapy-trial 2025-05-27T12:39:09+00:00 hourly 0.9 https://trial.medpath.com/news/987da6171374bd91/adc-market-in-nsclc-projected-to-reach-3-9-billion-by-2032-led-by-astrazeneca-s-datroway 2025-05-27T12:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/d74a3b3a1d989f15/vectory-therapeutics-appoints-jessica-atkinson-as-chief-business-officer-to-advance-neurodegenerative-disease-pipeline 2025-05-27T12:38:56+00:00 hourly 0.9 https://trial.medpath.com/news/dfbc3272b1669833/itm-secures-262-5m-debt-financing-to-support-commercial-launch-of-radiopharmaceutical-itm-11-following-positive-phase-3-results 2025-05-27T12:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/0b275b23e688fa18/beiersdorf-partners-with-vincere-biosciences-to-develop-mitophagy-based-anti-aging-skincare-solutions 2025-05-27T12:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/da600ae7c3ec252b/magnitude-biosciences-secures-ps700k-to-advance-high-throughput-drug-discovery-platform 2025-05-27T12:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/9af459780fe986ef/applied-cognition-achieves-first-continuous-human-glymphatic-monitoring-unlocking-new-alzheimer-s-drug-targets 2025-05-27T12:37:54+00:00 hourly 0.9 https://trial.medpath.com/news/0c7c25e3967127c6/selvita-becomes-first-cro-to-license-medicines-discovery-catapult-s-patented-target-engagement-technology 2025-05-27T12:37:53+00:00 hourly 0.9 https://trial.medpath.com/news/b8e68d5c332309f9/dll3-targeted-therapies-show-promise-for-refractory-small-cell-lung-cancer-despite-clinical-challenges 2025-05-27T12:37:47+00:00 hourly 0.9 https://trial.medpath.com/news/6ff8f7fe88ae1cb1/c4x-discovery-receives-eur8-million-milestone-from-sanofi-for-oral-il-17a-inhibitor-progress 2025-05-27T12:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/0f66e2a9ecc416e7/illumina-s-trusight-oncology-comprehensive-receives-regulatory-approval-in-japan-expanding-precision-cancer-care-access 2025-05-27T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/25f72571075308c7/sequana-medical-secures-eur-6-3-million-financing-to-support-alfapump-us-commercial-launch 2025-05-27T12:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/7b45aeb10d6072e1/sanofi-and-vnvc-launch-77-million-vaccine-manufacturing-facility-in-vietnam 2025-05-27T12:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/47e12a9a1c795545/pentixapharm-pivots-clinical-strategy-to-focus-on-cxcr4-targeted-theranostic-oncology-platform 2025-05-27T12:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/256c8af9736d23d0/world-adc-san-diego-conference-highlights-growing-industry-focus-on-antibody-drug-conjugates 2025-05-27T09:53:37+00:00 hourly 0.9 https://trial.medpath.com/news/d1d34cdc192e26a1/eisai-launches-dayvigo-first-orexin-receptor-antagonist-for-insomnia-treatment-in-china 2025-05-27T09:37:42+00:00 hourly 0.9 https://trial.medpath.com/news/ef15e6e7e6c62ea1/rnatives-secures-eur1-4m-seed-extension-to-advance-rna-based-gene-regulation-platform 2025-05-27T09:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/3ad1d370235cbaa8/mc2-therapeutics-names-trine-ahlgreen-as-ceo-to-drive-global-expansion-of-psoriasis-treatment-wynzora 2025-05-27T09:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/59ede10dfc1326d0/vivoryon-secures-key-u-s-patent-for-varoglutamstat-kidney-disease-treatment-through-2044 2025-05-27T09:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/afe81c9a0d529292/n4-pharma-assembles-expert-leadership-team-to-advance-nuvec-r-gene-delivery-platform 2025-05-27T09:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/70323b09a42f4599/oxford-brain-diagnostics-launches-revolutionary-mri-based-dementia-diagnosis-technology-following-fda-and-uk-regulatory-approvals 2025-05-27T09:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/0b5f995ee2220bf0/fda-approved-fgfr-inhibitors-show-promise-for-pediatric-brain-tumors-in-preclinical-studies 2025-05-27T03:45:03+00:00 hourly 0.9 https://trial.medpath.com/news/1a259d894502c09c/nsf-awards-500k-grant-to-advance-synthetic-dna-nanoparticles-for-targeted-gene-therapy 2025-05-27T02:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/c289f557985769aa/mabxience-expands-european-biosimilar-access-through-strategic-partnerships-with-abiogen-pharma-and-corapharm 2025-05-27T02:15:14+00:00 hourly 0.9 https://trial.medpath.com/news/42fea7e1cd7dc472/tokyo-researchers-develop-nasal-covid-vaccine-showing-superior-respiratory-immunity-in-animal-studies 2025-05-27T00:38:39+00:00 hourly 0.9 https://trial.medpath.com/news/3a2980e84ccf1b8c/dual-target-car-t-therapy-shows-promise-for-glioblastoma-with-24-5-month-median-survival 2025-05-27T00:38:35+00:00 hourly 0.9 https://trial.medpath.com/news/23548b3491b0dab2/chengdu-ucello-biotech-s-uc101-becomes-first-allogeneic-universal-car-t-therapy-to-receive-fda-ind-approval 2025-05-27T00:37:38+00:00 hourly 0.9 https://trial.medpath.com/news/fa1afb4342576e49/argentina-overhauls-drug-approval-process-mandates-placebo-controls-for-vaccine-trials 2025-05-27T00:37:08+00:00 hourly 0.9 https://trial.medpath.com/news/3b5ba8d3980126f9/onco-innovations-initiates-manufacturing-of-pnkp-inhibitor-for-preclinical-testing 2025-05-27T00:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/4e898dec92f3c16a/juri-biosciences-secures-global-rights-to-klk2-targeted-t-cell-engager-for-metastatic-prostate-cancer-in-210m-deal 2025-05-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/844942388195390c/eli-lilly-acquires-scorpion-s-cancer-drug-stx-478-in-2-5-billion-deal 2025-05-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/56b67ab6e681dc6a/enanta-pharmaceuticals-files-patent-infringement-lawsuit-against-pfizer-over-paxlovid 2025-05-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6052f599d7772d75/irlab-s-irl757-shows-promising-safety-profile-in-phase-i-trial-for-apathy-treatment-in-neurological-disorders 2025-05-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/625482aa0d5976c6/poxel-s-pxl065-shows-promise-in-preclinical-hypertrophic-cardiomyopathy-study-data-to-be-presented-at-esc-2025 2025-05-26T23:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/6ea95fb2c238b3d7/liv-hospital-partners-with-university-of-pennsylvania-to-establish-local-car-t-cell-manufacturing-in-turkey 2025-05-26T20:45:20+00:00 hourly 0.9 https://trial.medpath.com/news/369d0a8af83cbe9f/lupin-s-prmt5-inhibitor-lnp7457-shows-promising-safety-profile-in-phase-1-solid-tumor-trial 2025-05-26T20:44:41+00:00 hourly 0.9 https://trial.medpath.com/news/ac066b55f60f2283/novartis-launches-zero-interest-payment-plan-for-high-cost-cholesterol-drug-inclisiran-in-india 2025-05-26T20:44:40+00:00 hourly 0.9 https://trial.medpath.com/news/8eca559657d5b860/ruxolitinib-shows-superior-efficacy-in-steroid-refractory-chronic-gvhd-with-38-month-median-failure-free-survival 2025-05-26T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/83f889a7d7660874/nextcell-pharma-secures-us-patent-for-msc-prediction-algorithm-to-personalize-cell-therapy 2025-05-26T16:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/c9537b2674d23e7e/lunit-presents-12-ai-powered-studies-at-asco-2025-demonstrating-enhanced-cancer-treatment-selection 2025-05-26T16:38:55+00:00 hourly 0.9 https://trial.medpath.com/news/8b5cd70996a48cd0/huonslab-completes-patient-enrollment-in-phase-1-pivotal-study-for-recombinant-human-natural-killer-cell-therapy 2025-05-26T16:37:51+00:00 hourly 0.9